<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02156466</url>
  </required_header>
  <id_info>
    <org_study_id>200574-003</org_study_id>
    <secondary_id>2013-005436-18</secondary_id>
    <nct_id>NCT02156466</nct_id>
  </id_info>
  <brief_title>Multiple Ascending Dose Trial of MSB0010841 (Anti-IL17A/F Nanobody) in Psoriasis Subjects</brief_title>
  <official_title>Multicenter, Phase I, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety, Tolerability, Immunogenicity, Pharmacokinetics, Pharmacodynamics and Efficacy of Multiple Ascending Doses of Subcutaneous MSB0010841 (Anti-IL17A/F Nanobody) in Male and Female Subjects With Moderate to Severe Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck KGaA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck KGaA</source>
  <brief_summary>
    <textblock>
      This is a multicenter, Phase 1, randomized, double-blind, placebo-controlled trial in
      subjects with moderate to severe psoriasis to assess the safety, tolerability,
      immunogenicity, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of multiple
      subcutaneous ascending doses of MSB0010841 (Anti-interleukin-17A/F [Anti-IL-17A/F] Nanobody).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects With Treatment Emergent Adverse Events (TEAEs)</measure>
    <time_frame>Baseline up to Day 85</time_frame>
    <description>An adverse event (AE) was defined as any untoward medical occurrence which does not necessarily have a causal relationship with this the study drug. An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug or worsening of pre-existing medical condition, whether or not related to study drug. TEAEs were the AEs occurring or worsening after treatment administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Local Injection Site Reactions (ISRs)</measure>
    <time_frame>Day 1, 2,8, 15, 16, 22, 29, 30, 36, 43</time_frame>
    <description>The injection site was assessed by the Principal Investigator (PI) or his/her designee for local reactions such as redness, swelling, indurations or bruising, and by the subject for itching. Redness and bruising were scaled as None (no visible redness or bruising present); Mild (less than or equal to [&lt;=] 2.0 centimeters [cm] redness or bruising area); Moderate (greater than [&gt;] 2 to &lt;=5.0 cm redness or bruising area); Severe (&gt;5.0 cm redness or bruising area). Swelling was scaled as None (no swelling detected); Mild (palpable 'firmness' only); Moderate (&lt;= 4 cm swelling); Severe (&gt;4 cm swelling). Induration was scaled as None (no induration); Mild (able to move skin parallel to plane (sliding) and perpendicular to skin (pinching up); Moderate (able to slide skin, unable to pinch skin); Severe (unable to slide or pinch skin). Itching was scaled as No itching; Mild itching; Moderate itching and Severe itching. Subjects who reported any of the local ISRs were reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount of Pain at Injection Site Assessed By Visual Analog Scale (VAS)</measure>
    <time_frame>Day 1, 2, 8, 15, 16, 22, 29, 30, 36, 43</time_frame>
    <description>Subjects were asked to assess their severity of injection site pain on a 100 millimeter (mm) VAS, where 0 = no pain and 100 = worst possible pain. Mean of amount of pain was calculated for the subjects having a value &gt; 0. Maximum values per subjects (over injection site areas) are used for counting the amount of pain at injection site. Maximum pain scores recorded among all participants analysed in each arm are reported for each time point.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Subjects With Anti-MSB0010841 Binding Antibodies (Anti-Drug Antibodies [ADA])</measure>
    <time_frame>Baseline up to Day 85</time_frame>
    <description>Data were presented for MSB0010841 combined group and placebo.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Levels of Anti-MSB0010841 Antibody Titers</measure>
    <time_frame>Day 8, 15 (pre-dose), 22, 29 (pre-dose), 36, 43, 63 and 85</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Levels of Pre-existing Anti-MSB0010841 Antibody Titers</measure>
    <time_frame>Pre-dose on Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>MSB0010841 Serum Concentration Over Time After First Dose</measure>
    <time_frame>0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-first dose (Day 1)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>MSB0010841 Serum Concentration Over Time After Second Dose</measure>
    <time_frame>0 hours (pre-dose), 24, 72, 96, 168, 336 hours post-second dose (Day 15)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>MSB0010841 Serum Concentration Over Time After Third Dose</measure>
    <time_frame>0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) Post First Dose of MSB0010841</measure>
    <time_frame>0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-first dose (Day 1)</time_frame>
    <description>Area under the serum concentration-time curve (AUC) from time zero to the last sampling time point at which the concentration is at or above lower limit of quantification (LLOQ).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) Post Third Dose of MSB0010841</measure>
    <time_frame>0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)</time_frame>
    <description>Area under the serum concentration-time curve (AUC) from time zero to the last sampling time point at which the concentration is at or above LLOQ.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration-Time Curve From Time Zero up to Time Tau (AUCtau) Post First Dose of MSB0010841</measure>
    <time_frame>0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-first dose (Day 1)</time_frame>
    <description>Area under the concentration-time curve from time zero up to time Tau, where Tau is the dosing interval (336 hours).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration-Time Curve From Time Zero up to Time Tau (AUCtau) Post Third Dose of MSB0010841</measure>
    <time_frame>0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-third dose (Day 29)</time_frame>
    <description>Area under the concentration-time curve from time zero up to time Tau, where Tau is the dosing interval (336 hours).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration-time Curve From Time Zero to Infinity (AUC 0-inf) Post Third Dose of MSB0010841</measure>
    <time_frame>0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)</time_frame>
    <description>Area under the serum concentration-time curve from time zero to infinity (AUC0-inf). AUC0-infcalculated as AUC0-t + AUCextra. AUCextra represents the extrapolated part of AUC0-inf calculated by Clast calc/λz, where Clast calc is the calculated concentration at the last sampling time point at which the measured concentration is at or above LLOQ and λz is the terminal rate constant determined from the terminal slope of the log transformed concentration curve using linear regression on terminal data points of the curve.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Observed Serum Concentration Immediately Before First Dose (Cpre) of MSB0010841</measure>
    <time_frame>Pre-dose (0 hours) on Day 1</time_frame>
    <description>The observed serum concentration immediately before the first dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Observed Serum Concentration Immediately Before Third Dose (Cpre) of MSB0010841</measure>
    <time_frame>Pre-dose (0 hours) on Day 29</time_frame>
    <description>The observed serum concentration immediately before the third dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Minimum Concentration Observed (Cmin) During First Dosing Interval of MSB0010841</measure>
    <time_frame>0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-first dose (Day 1)</time_frame>
    <description>The observed minimum serum concentration determined directly from the serum concentration-time profile of each subject.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Minimum Concentration Observed (Cmin) During Third Dosing Interval of MSB0010841</measure>
    <time_frame>0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)</time_frame>
    <description>The observed minimum serum concentration determined directly from the serum concentration-time profile of each subject.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Concentration Observed (Cmax) Post First Dose of MSB0010841</measure>
    <time_frame>0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-first dose (Day 1)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Concentration Observed (Cmax) Post Third Dose of MSB0010841</measure>
    <time_frame>0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Average Concentration (Cav) Post First Dose of MSB0010841</measure>
    <time_frame>0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-first dose (Day 1)</time_frame>
    <description>Cav was calculated by AUCtau/tau. Where tau is the dosing interval (336 hours).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Average Concentration (Cav) Post Third Dose of MSB0010841</measure>
    <time_frame>0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)</time_frame>
    <description>Cav was calculated by AUCtau/tau. Where tau is the dosing interval (336 hours).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Residence Time (MRT0-t) Post First Dose of MSB0010841</measure>
    <time_frame>0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-first dose (Day 1)</time_frame>
    <description>MRT is the average time at which the number of absorbed molecules reside in the body, after single-dose administration, and calculated as AUMC(0-t)/AUC(0-t) where AUMC(0-t) is area under the plasma concentration-time first moment curve from time zero to time t (336 hours) and AUC(0-t) is the area under the plasma concentration-time curve from time zero to tome t (336 hours).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Residence Time (MRT0-t) Post Third Dose of MSB0010841</measure>
    <time_frame>0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-third dose (Day 29)</time_frame>
    <description>MRT is the average time at which the number of absorbed molecules reside in the body, after single-dose administration, and calculated as AUMC(0-t)/AUC(0-t) where AUMC(0-t) is area under the plasma concentration-time first moment curve from time zero to time t (336 hours) and AUC(0-t) is the area under the plasma concentration-time curve from time zero to tome t (336 hours).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Residence Time of Drug in the Body From Time Zero Extrapolated to Infinity (MRT(0-inf) Post Third Dose of MSB0010841</measure>
    <time_frame>0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)</time_frame>
    <description>Mean residence time of drug in the body from time zero extrapolated to infinity, based on the last predicted concentration at tlast.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Reach Maximum Observed Concentration (Tmax) Post First Dose of MSB0010841</measure>
    <time_frame>0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-first dose (Day 1)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Maximum Observed Concentration (Tmax) Post Second Dose of MSB0010841</measure>
    <time_frame>0 hours (pre-dose), 24, 72, 96, 168, 336 hours post-second dose (Day 15)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Reach Maximum Observed Concentration (Tmax) Post Third Dose of MSB0010841</measure>
    <time_frame>0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Terminal Half-life (t1/2) Post Third Dose of MSB0010841</measure>
    <time_frame>0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)</time_frame>
    <description>Terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life is calculated by dividing the natural logarithm to the base e (Log e) multiplied by (*) 2/ λz, where 'λz' is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal Rate Constant (λz) Post Third Dose of MSB0010841</measure>
    <time_frame>0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)</time_frame>
    <description>Terminal rate constant was determined from the terminal slope of the logtransformed concentration curve using linear regression on terminal data points of the curve</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Clearance (CL/f) Post Third Dose of MSB0010841</measure>
    <time_frame>0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)</time_frame>
    <description>Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent clearance after oral dose (CL/f) is influenced by the fraction absorbed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Volume of Distribution During Terminal Phase (Vz/f) Post Third Dose of MSB0010841</measure>
    <time_frame>0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)</time_frame>
    <description>Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. Apparent volume of distribution during the terminal phase, calculated as Vz = Dose/AUC0-inf multiplied by elimination rate constant [λz]) following first dose and Dose/(AUCtau multiplied by λz) after third dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage Peak-Trough Fluctuation (PTF) Post First Dose of MSB0010841</measure>
    <time_frame>0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-first dose (Day 1)</time_frame>
    <description>The peak trough fluctuation within one dosing interval, calculated as PTF (%) = ([Cmax - Cmin]/Cav ) multiplied by 100</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage Peak-Trough Fluctuation (PTF) Post Third Dose of MSB0010841</measure>
    <time_frame>0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)</time_frame>
    <description>The peak trough fluctuation within one dosing interval, calculated as PTF (%) = ([Cmax - Cmin]/Cav ) multiplied by 100</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Accumulation Ratio of Cmax (Racc (Cmax))</measure>
    <time_frame>0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-first dose (Day 1) and 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)</time_frame>
    <description>Accumulation ratio for Cmax was calculated as Cmax, after third dose / Cmax, after first dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Accumulation Ratio of AUC (Racc(AUC))</measure>
    <time_frame>0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-first dose (Day 1) and 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)</time_frame>
    <description>Accumulation ratio for AUC, calculated as area under the serum concentration-time curve within one complete dosing interval at third dose divided by area under the serum concentration-time curve within one complete dosing interval at first dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Concentration (Cmax) Post Second Dose of MSB0010841</measure>
    <time_frame>0 hours (pre-dose), 24, 72, 96, 168, 336 hours post-second dose (Day 15)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Observed Serum Concentration Immediately Before Second Dose (Cpre) of MSB0010841</measure>
    <time_frame>Pre-dose (0 hours) on Day 15</time_frame>
    <description>The observed serum concentration immediately before second dose.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With 50% or 75% Improvement From Baseline in Psoriasis Area and Severity Index (PASI) Score</measure>
    <time_frame>Baseline up to Day 85</time_frame>
    <description>PASI: a physician assessed index that measured psoriasis severity and evaluated erythema, infiltration, and desquamation (scaling) on different body areas including the head, upper extremities, the trunk, and lower extremities. T Erythema, infiltration, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) was multiplied by the degree of involvement for each anatomic region and then multiplied by a constant. These values for each anatomic region are summed to yield the PASI score. PASI score ranged from 0 to 72, with higher scores reflecting greater disease severity. PASI 50% or 75% was defined as the percentage of participants who achieved &gt;=50 or 75% improvement in PASI score from Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Day 43</measure>
    <time_frame>Baseline, Day 43</time_frame>
    <description>PASI: a physician assessed index that measured psoriasis severity and evaluated erythema, infiltration, and desquamation (scaling) on different body areas including the head, upper extremities, the trunk, and lower extremities. T Erythema, infiltration, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) was multiplied by the degree of involvement for each anatomic region and then multiplied by a constant. These values for each anatomic region are summed to yield the PASI score. PASI score ranged from 0 to 72, with higher scores reflecting greater disease severity. PASI 50% or 75% was defined as the percentage of subjects who achieved &gt;=50 or 75% improvement in PASI score from Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Static Physician's Global Assessment (sPGA) Score of Minimal or Clear and With at Least 2 Level Reduction From Baseline</measure>
    <time_frame>Day 8, 15, 22, 29, 36, 43, 50, 85</time_frame>
    <description>The static Physician's Global Assessment (sPGA) scale rated the investigator's overall clinical assessment of a subjects plaque thickness, erythema, and scaling on a 6-point scale ranging from 0 (clear, except for residual discoloration) to 5 (majority of plaques have severe thickness, erythema, and scale). To assign a sPGA score, the investigator examined all psoriatic lesions and assigned a severity score ranging from 0 to 5 for thickness, erythema, and scaling. Scores for thickness, erythema, and scaling are summed and the mean of these 3 scores equals the overall sPGA score. Overall sPGA score ranged from 0 to 5, where lower scores indicate clinical improvement. Percentage of subjects who achieved a sPGA rating of 0 (clear) or 1 (minimal) and had at Least 2 level reduction from Baseline score were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Percent Change From Baseline in the Body Surface Area (BSA) Affected by Psoriasis at Day 8, 15, 22, 29, 36, 43, 50 and 85</measure>
    <time_frame>Baseline, Day 8, 15, 22, 29, 36, 43, 50 and 85</time_frame>
    <description>The BSA is the physician's evaluation for the extent of disease. The entire body area is divided into 4 districts: head, upper limbs, trunk and lower limbs to which corresponds the 10%, 20%, 30% and 40% of the entire body surface respectively. The investigator assesses the percentage of the subjects' body surface area affected by psoriasis in each district. The final affected BSA value is the sum of the percentage of each district.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Exacerbation of Psoriasis</measure>
    <time_frame>Baseline up to Day 85</time_frame>
    <description>Psoriasis exacerbation was defined as either a worsening of 25% over the baseline value of the PASI score (PASI score at any visit &gt;=125% of baseline PASI).</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>MSB0010841 30 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MSB0010841 60 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MSB0010841 120 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MSB0010841 240 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MSB0010841</intervention_name>
    <description>MSB0010841(Anti- IL-17A/F Nanobody) will be administered at a dose of 30 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
    <arm_group_label>MSB0010841 30 mg</arm_group_label>
    <other_name>Anti-IL-17A/F Nanobody</other_name>
    <other_name>M1095</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MSB0010841</intervention_name>
    <description>MSB0010841 will be administered at a dose of 60 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
    <arm_group_label>MSB0010841 60 mg</arm_group_label>
    <other_name>Anti-IL-17A/F Nanobody</other_name>
    <other_name>M1095</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MSB0010841</intervention_name>
    <description>MSB0010841 will be administered at a dose of 120 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
    <arm_group_label>MSB0010841 120 mg</arm_group_label>
    <other_name>Anti-IL-17A/F Nanobody</other_name>
    <other_name>M1095</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MSB0010841</intervention_name>
    <description>MSB0010841 will be administered at a dose of 240 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
    <arm_group_label>MSB0010841 240 mg</arm_group_label>
    <other_name>Anti-IL-17A/F Nanobody</other_name>
    <other_name>M1095</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matched to MSB0010841 will be administered as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic plaque psoriasis for at least 6 months before screening

          -  Greater than or equal to (&gt;=) 10% of BSA with plaques

          -  Psoriasis Area and Severity Index (PASI) &gt;=12

          -  Static Physician's Global Assessment (sPGA) &gt;=3 (where scores range from 0 [clear of
             disease] to 5 [severe disease]) at the screening and baseline visits

          -  Other protocol defined inclusion criteria could apply

        Exclusion Criteria:

          -  Any condition, including protocol-specified laboratory findings and findings in the
             medical history or in the pre-trial assessments which in the Investigator's opinion
             constitutes a risk or a contraindication for the subject's participation in the trial
             or that could interfere with the trial objectives, conduct or evaluation

          -  Currently having a form of non-plaque psoriasis as specified in the protocol

          -  Drug induced psoriasis

          -  Biological treatments as specified in the protocol, within 3 months prior to Day 1

          -  Systemic immunosuppressants or phototherapy as specified in the protocol, within 1
             month prior to Day 1

          -  Use of anti-coagulant medications and/or antiplatelet medications as defined in the
             protocol

          -  Use of aspirin as defined in the protocol

          -  Topical corticosteroid treatments other than low-strength or lower-mid strength
             corticosteroids on the face, scalp, axillae, and/or groin within 1 month prior to Day
             1

          -  Any previous treatment with an agent targeting interleukin (IL)-17, IL-12 and/or IL-23
             as specified in the protocol

          -  Other protocol defined exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Responsible</last_name>
    <role>Study Director</role>
    <affiliation>Merck KGaA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Please contact the Merck KGaA Communication Center</name>
      <address>
        <city>Darmstadt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 23, 2014</study_first_submitted>
  <study_first_submitted_qc>June 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2014</study_first_posted>
  <results_first_submitted>August 24, 2016</results_first_submitted>
  <results_first_submitted_qc>November 28, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 19, 2017</results_first_posted>
  <last_update_submitted>November 28, 2016</last_update_submitted>
  <last_update_submitted_qc>November 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Psoriasis</keyword>
  <keyword>MSB0010841</keyword>
  <keyword>Anti-IL17A/F Nanobody</keyword>
  <keyword>M1095</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 41 subjects were randomized in the trial and included in the Safety analysis set.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>MSB0010841 30 mg</title>
          <description>MSB0010841 (Anti-Interleukin [IL]-17A/F Nanobody) was administered at a dose of 30 milligram (mg) as subcutaneous (SC) injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
        </group>
        <group group_id="P2">
          <title>MSB0010841 60 mg</title>
          <description>MSB0010841 was administered at a dose of 60 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
        </group>
        <group group_id="P3">
          <title>MSB0010841 120 mg</title>
          <description>MSB0010841 was administered at a dose of 120 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
        </group>
        <group group_id="P4">
          <title>MSB0010841 240 mg</title>
          <description>MSB0010841 was administered at a dose of 240 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
        </group>
        <group group_id="P5">
          <title>Placebo</title>
          <description>Placebo matched to MSB0010841 was administered as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Quantiferon Positivity</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety analysis set included all 41 subjects who received at least 1 dose of investigational medicinal product (IMP) (MSB0010841 or placebo).</population>
      <group_list>
        <group group_id="B1">
          <title>MSB0010841 30 mg</title>
          <description>MSB0010841 (Anti- IL-17A/F Nanobody) was administered at a dose of 30 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
        </group>
        <group group_id="B2">
          <title>MSB0010841 60 mg</title>
          <description>MSB0010841 was administered at a dose of 60 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
        </group>
        <group group_id="B3">
          <title>MSB0010841 120 mg</title>
          <description>MSB0010841 was administered at a dose of 120 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
        </group>
        <group group_id="B4">
          <title>MSB0010841 240 mg</title>
          <description>MSB0010841 was administered at a dose of 240 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Placebo</title>
          <description>Placebo matched to MSB0010841 was administered as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="9"/>
            <count group_id="B5" value="8"/>
            <count group_id="B6" value="41"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.6" spread="13.24"/>
                    <measurement group_id="B2" value="42.1" spread="19.57"/>
                    <measurement group_id="B3" value="43.8" spread="13.59"/>
                    <measurement group_id="B4" value="44.8" spread="15.65"/>
                    <measurement group_id="B5" value="46.1" spread="14.57"/>
                    <measurement group_id="B6" value="45.1" spread="14.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Treatment Emergent Adverse Events (TEAEs)</title>
        <description>An adverse event (AE) was defined as any untoward medical occurrence which does not necessarily have a causal relationship with this the study drug. An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug or worsening of pre-existing medical condition, whether or not related to study drug. TEAEs were the AEs occurring or worsening after treatment administration.</description>
        <time_frame>Baseline up to Day 85</time_frame>
        <population>Safety analysis set included all 41 subjects who received at least 1 dose of IMP (MSB0010841 or placebo).</population>
        <group_list>
          <group group_id="O1">
            <title>MSB0010841 30 mg</title>
            <description>MSB0010841 (Anti- IL-17A/F Nanobody) was administered at a dose of 30 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>MSB0010841 60 mg</title>
            <description>MSB0010841 was administered at a dose of 60 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>MSB0010841 120 mg</title>
            <description>MSB0010841 was administered at a dose of 120 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O4">
            <title>MSB0010841 240 mg</title>
            <description>MSB0010841 was administered at a dose of 240 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo matched to MSB0010841 was administered as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Treatment Emergent Adverse Events (TEAEs)</title>
          <description>An adverse event (AE) was defined as any untoward medical occurrence which does not necessarily have a causal relationship with this the study drug. An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug or worsening of pre-existing medical condition, whether or not related to study drug. TEAEs were the AEs occurring or worsening after treatment administration.</description>
          <population>Safety analysis set included all 41 subjects who received at least 1 dose of IMP (MSB0010841 or placebo).</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Local Injection Site Reactions (ISRs)</title>
        <description>The injection site was assessed by the Principal Investigator (PI) or his/her designee for local reactions such as redness, swelling, indurations or bruising, and by the subject for itching. Redness and bruising were scaled as None (no visible redness or bruising present); Mild (less than or equal to [&lt;=] 2.0 centimeters [cm] redness or bruising area); Moderate (greater than [&gt;] 2 to &lt;=5.0 cm redness or bruising area); Severe (&gt;5.0 cm redness or bruising area). Swelling was scaled as None (no swelling detected); Mild (palpable ‘firmness’ only); Moderate (&lt;= 4 cm swelling); Severe (&gt;4 cm swelling). Induration was scaled as None (no induration); Mild (able to move skin parallel to plane (sliding) and perpendicular to skin (pinching up); Moderate (able to slide skin, unable to pinch skin); Severe (unable to slide or pinch skin). Itching was scaled as No itching; Mild itching; Moderate itching and Severe itching. Subjects who reported any of the local ISRs were reported.</description>
        <time_frame>Day 1, 2,8, 15, 16, 22, 29, 30, 36, 43</time_frame>
        <population>Safety analysis set included all 41 subjects who received at least one dose of IMP (MSB0010841 or placebo). Here “n” signifies those subjects who were evaluable for the specified injection site reaction. Subjects may be represented in more than 1 category.</population>
        <group_list>
          <group group_id="O1">
            <title>MSB0010841 30 mg</title>
            <description>MSB0010841 (Anti- IL-17A/F Nanobody) was administered at a dose of 30 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>MSB0010841 60 mg</title>
            <description>MSB0010841 was administered at a dose of 60 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>MSB0010841 120 mg</title>
            <description>MSB0010841 was administered at a dose of 120 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O4">
            <title>MSB0010841 240 mg</title>
            <description>MSB0010841 was administered at a dose of 240 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo matched to MSB0010841 was administered as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Local Injection Site Reactions (ISRs)</title>
          <description>The injection site was assessed by the Principal Investigator (PI) or his/her designee for local reactions such as redness, swelling, indurations or bruising, and by the subject for itching. Redness and bruising were scaled as None (no visible redness or bruising present); Mild (less than or equal to [&lt;=] 2.0 centimeters [cm] redness or bruising area); Moderate (greater than [&gt;] 2 to &lt;=5.0 cm redness or bruising area); Severe (&gt;5.0 cm redness or bruising area). Swelling was scaled as None (no swelling detected); Mild (palpable ‘firmness’ only); Moderate (&lt;= 4 cm swelling); Severe (&gt;4 cm swelling). Induration was scaled as None (no induration); Mild (able to move skin parallel to plane (sliding) and perpendicular to skin (pinching up); Moderate (able to slide skin, unable to pinch skin); Severe (unable to slide or pinch skin). Itching was scaled as No itching; Mild itching; Moderate itching and Severe itching. Subjects who reported any of the local ISRs were reported.</description>
          <population>Safety analysis set included all 41 subjects who received at least one dose of IMP (MSB0010841 or placebo). Here “n” signifies those subjects who were evaluable for the specified injection site reaction. Subjects may be represented in more than 1 category.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 Bruising: none (n=8,8,8,9,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 Indurations: none (n=8,8,8,9,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 Indurations: mild (n=8,8,8,9,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 Itching: none (n=8,8,8,9,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 Itching: mild (n=8,8,8,9,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 Redness: none (n=8,8,8,9,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 Redness: mild (n=8,8,8,9,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 Swelling: none (n=8,8,8,9,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 Swelling: mild (n=8,8,8,9,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 Bruising: none (n=8,8,8,9,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 Bruising: mild (n=8,8,8,9,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 Indurations: none (n=8,8,8,9,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 Itching: none (n=8,8,8,9,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 Redness: none (n=8,8,8,9,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 Swelling: none (n=8,8,8,9,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8 Bruising: none (n=8,8,8,8,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8 Indurations: none (n=8,8,8,8,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8 Itching: none (n=8,8,8,8,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8 Redness: none (n=8,8,8,8,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8 Redness: mild (n=8,8,8,8,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8 Swelling: none (n=8,8,8,8,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 Bruising: none (n=8,8,8,8,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 Indurations: none (n=8,8,8,8,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 Itching: none (n=8,8,8,8,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 Redness: none (n=8,8,8,8,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 Redness: mild (n=8,8,8,8,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 Redness: moderate (n=8,8,8,8,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 Swelling: none (n=8,8,8,8,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 16 Bruising: none (n=8,8,8,8,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 16 Bruising: mild (n=8,8,8,8,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 16 Indurations: none (n=8,8,8,8,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 16 Itching: none (n=8,8,8,8,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 16 Redness: none (n=8,8,8,8,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 16 Redness: mild (n=8,8,8,8,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 16 Swelling: none (n=8,8,8,8,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 16 Swelling: mild (n=8,8,8,8,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22 Bruising: none (n=8,8,8,8,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22 Bruising: mild (n=8,8,8,8,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22 Indurations: none (n=8,8,8,8,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22 Indurations: severe (n=8,8,8,8,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22 Itching: none (n=8,8,8,8,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22 Itching: mild (n=8,8,8,8,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22 Redness: none (n=8,8,8,8,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22 Redness: severe (n=8,8,8,8,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22 Swelling: none (n=8,8,8,8,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22 Swelling: severe (n=8,8,8,8,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 Bruising: none (n=8,8,8,7,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 Indurations: none (n=8,8,7,7,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 Itching: none (n=8,8,8,7,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 Redness: none (n=8,8,8,8,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 Redness: mild (n=8,8,8,8,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 Redness: moderate (n=8,8,8,8,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 Swelling: none (n=8,8,8,7,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 Swelling: mild (n=8,8,8,7,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30 Bruising: none (n=8,8,8,7,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30 Bruising: mild (n=8,8,8,7,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30 Indurations: none (n=8,8,7,7,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30 Itching: none (n=8,8,7,7,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30 Redness: none (n==8,8,7,7,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30 Redness: moderate (n=8,8,7,7,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30 Swelling: none (n=8,8,7,7,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 36 Bruising: none (n=7,8,7,7,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 36 Bruising: mild (n=7,8,7,7,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 36 Indurations: none (n=8,8,7,7,7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 36 Itching: none (n=7,8,7,6,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43 Bruising: none (n=8,8,8,8,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43 Indurations: none (n=8,8,8,8,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43 Itching: none (8,8,8,8,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43 Redness: none (n=8,8,8,8,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43 Redness: moderate (n=8,8,8,8,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43 Swelling: none (n=8,8,8,8,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Amount of Pain at Injection Site Assessed By Visual Analog Scale (VAS)</title>
        <description>Subjects were asked to assess their severity of injection site pain on a 100 millimeter (mm) VAS, where 0 = no pain and 100 = worst possible pain. Mean of amount of pain was calculated for the subjects having a value &gt; 0. Maximum values per subjects (over injection site areas) are used for counting the amount of pain at injection site. Maximum pain scores recorded among all participants analysed in each arm are reported for each time point.</description>
        <time_frame>Day 1, 2, 8, 15, 16, 22, 29, 30, 36, 43</time_frame>
        <population>Safety analysis set included all 41 subjects who received at least one dose of IMP (MSB0010841 or placebo). Here “Number of subjects analyzed” signifies those subjects who were evaluable for this endpoint and “n” signifies those subjects who were evaluable at the specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>MSB0010841 30 mg</title>
            <description>MSB0010841 (Anti- IL-17A/F Nanobody) was administered at a dose of 30 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>MSB0010841 60 mg</title>
            <description>MSB0010841 was administered at a dose of 60 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>MSB0010841 120 mg</title>
            <description>MSB0010841 was administered at a dose of 120 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O4">
            <title>MSB0010841 240 mg</title>
            <description>MSB0010841 was administered at a dose of 240 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo matched to MSB0010841 was administered as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Amount of Pain at Injection Site Assessed By Visual Analog Scale (VAS)</title>
          <description>Subjects were asked to assess their severity of injection site pain on a 100 millimeter (mm) VAS, where 0 = no pain and 100 = worst possible pain. Mean of amount of pain was calculated for the subjects having a value &gt; 0. Maximum values per subjects (over injection site areas) are used for counting the amount of pain at injection site. Maximum pain scores recorded among all participants analysed in each arm are reported for each time point.</description>
          <population>Safety analysis set included all 41 subjects who received at least one dose of IMP (MSB0010841 or placebo). Here “Number of subjects analyzed” signifies those subjects who were evaluable for this endpoint and “n” signifies those subjects who were evaluable at the specified time point.</population>
          <units>mm</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (n=3,2,3,2,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="NA">Data could not be calculated as there were no subjects with amount of pain value of &gt; 0 at the specified time point</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 (n=1,1,1,1,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="NA">Data could not be calculated as there were no subjects with amount of pain value of &gt; 0 at the specified time point</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8 (n=1,1,0,0,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="NA">Data could not be calculated as there were no subjects with amount of pain value of &gt; 0 at the specified time point</measurement>
                    <measurement group_id="O4" value="NA">Data could not be calculated as there were no subjects with amount of pain value of &gt; 0 at the specified time point</measurement>
                    <measurement group_id="O5" value="NA">Data could not be calculated as there were no subjects with amount of pain value of &gt; 0 at the specified time point</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 (n=2,1,3,0,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="NA">Data could not be calculated as there were no subjects with amount of pain value of &gt; 0 at the specified time point</measurement>
                    <measurement group_id="O5" value="NA">Data could not be calculated as there were no subjects with amount of pain value of &gt; 0 at the specified time point</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 16 (n=0,0,0,0,2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data could not be calculated as there were no subjects with amount of pain value of &gt; 0 at the specified time point</measurement>
                    <measurement group_id="O2" value="NA">Data could not be calculated as there were no subjects with amount of pain value of &gt; 0 at the specified time point</measurement>
                    <measurement group_id="O3" value="NA">Data could not be calculated as there were no subjects with amount of pain value of &gt; 0 at the specified time point</measurement>
                    <measurement group_id="O4" value="NA">Data could not be calculated as there were no subjects with amount of pain value of &gt; 0 at the specified time point</measurement>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22 (1,0,1,0,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="NA">Data could not be calculated as there were no subjects with amount of pain value of &gt; 0 at the specified time point</measurement>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="NA">Data could not be calculated as there were no subjects with amount of pain value of &gt; 0 at the specified time point</measurement>
                    <measurement group_id="O5" value="NA">Data could not be calculated as there were no subjects with amount of pain value of &gt; 0 at the specified time point</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (n=1,1,1,0,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="NA">Data could not be calculated as there were no subjects with amount of pain value of &gt; 0 at the specified time point</measurement>
                    <measurement group_id="O5" value="NA">Data could not be calculated as there were no subjects with amount of pain value of &gt; 0 at the specified time point</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30 (1,0,1,1,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="NA">Data could not be calculated as there were no subjects with amount of pain value of &gt; 0 at the specified time point</measurement>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="NA">Data could not be calculated as there were no subjects with amount of pain value of &gt; 0 at the specified time point</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 36 (n=0,0,0,0,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data could not be calculated as there were no subjects with amount of pain value of &gt; 0 at the specified time point</measurement>
                    <measurement group_id="O2" value="NA">Data could not be calculated as there were no subjects with amount of pain value of &gt; 0 at the specified time point</measurement>
                    <measurement group_id="O3" value="NA">Data could not be calculated as there were no subjects with amount of pain value of &gt; 0 at the specified time point</measurement>
                    <measurement group_id="O4" value="NA">Data could not be calculated as there were no subjects with amount of pain value of &gt; 0 at the specified time point</measurement>
                    <measurement group_id="O5" value="NA">Data could not be calculated as there were no subjects with amount of pain value of &gt; 0 at the specified time point</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43 (n=0,0,0,0,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data could not be calculated as there were no subjects with amount of pain value of &gt; 0 at the specified time point</measurement>
                    <measurement group_id="O2" value="NA">Data could not be calculated as there were no subjects with amount of pain value of &gt; 0 at the specified time point</measurement>
                    <measurement group_id="O3" value="NA">Data could not be calculated as there were no subjects with amount of pain value of &gt; 0 at the specified time point</measurement>
                    <measurement group_id="O4" value="NA">Data could not be calculated as there were no subjects with amount of pain value of &gt; 0 at the specified time point</measurement>
                    <measurement group_id="O5" value="NA">Data could not be calculated as there were no subjects with amount of pain value of &gt; 0 at the specified time point</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects With Anti-MSB0010841 Binding Antibodies (Anti-Drug Antibodies [ADA])</title>
        <description>Data were presented for MSB0010841 combined group and placebo.</description>
        <time_frame>Baseline up to Day 85</time_frame>
        <population>Safety analysis set included all 41 subjects who received at least one dose of IMP (MSB0010841 or placebo).</population>
        <group_list>
          <group group_id="O1">
            <title>MSB0010841 Combined</title>
            <description>All subjects who received MSB0010841 (Anti-IL-17A/F Nanobody) at a dose of 30 mg, 60 mg, 120 mg or 240 mg as subcutaneous (SC) injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matched to MSB0010841 was administered as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Anti-MSB0010841 Binding Antibodies (Anti-Drug Antibodies [ADA])</title>
          <description>Data were presented for MSB0010841 combined group and placebo.</description>
          <population>Safety analysis set included all 41 subjects who received at least one dose of IMP (MSB0010841 or placebo).</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.3"/>
                    <measurement group_id="O2" value="37.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Levels of Anti-MSB0010841 Antibody Titers</title>
        <time_frame>Day 8, 15 (pre-dose), 22, 29 (pre-dose), 36, 43, 63 and 85</time_frame>
        <population>All subjects who received placebo or MSB0010841 (30 mg, 60 mg, 90 mg or 240 mg) and had positive ADA titers before and/or after study drug administration were included in the analysis population.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA Positive Subjects</title>
            <description>All subjects who received placebo or MSB0010841 (30 mg, 60 mg, 90 mg or 240 mg) and had positive ADA titers before and/or after study drug administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Levels of Anti-MSB0010841 Antibody Titers</title>
          <population>All subjects who received placebo or MSB0010841 (30 mg, 60 mg, 90 mg or 240 mg) and had positive ADA titers before and/or after study drug administration were included in the analysis population.</population>
          <units>log10titer</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 8 Subject 1: Placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8 Subject 2: Placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8 Subject 3: Placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8 Subject 4: MSB0010841 30 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8 Subject 5: MSB0010841 30 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8 Subject 6: MSB0010841 30 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8 Subject 7: MSB0010841 60 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8 Subject 8: MSB0010841 120 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8 Subject 9: MSB0010841 120 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8 Subject 10: MSB0010841 120 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8 Subject 11: MSB0010841 120 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8 Subject 12: MSB0010841 120 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8 Subject 13: MSB0010841 240 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 (pre-dose) Subject 1: Placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 (pre-dose) Subject 2: Placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 (pre-dose) Subject 3: Placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 (pre-dose) Subject 4: MSB0010841 30 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 (pre-dose) Subject 5: MSB0010841 30 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 (pre-dose) Subject 6: MSB0010841 30 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 (pre-dose) Subject 7: MSB0010841 60 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 (pre-dose) Subject 8: MSB0010841 120 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 (pre-dose) Subject 9: MSB0010841 120 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 (pre-dose) Subject 10: MSB0010841 120 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 (pre-dose) Subject 11: MSB0010841 120 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 (pre-dose) Subject 12: MSB0010841 120 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 (pre-dose) Subject 13: MSB0010841 240 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22 Subject 1: Placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22 Subject 2: Placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22 Subject 3: Placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22 Subject 4: MSB0010841 30 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22 Subject 5: MSB0010841 30 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22 Subject 6: MSB0010841 30 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22 Subject 7: MSB0010841 60 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22 Subject 8: MSB0010841 120 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22 Subject 9: MSB0010841 120 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22 Subject 10: MSB0010841 120 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22 Subject 11: MSB0010841 120 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22 Subject 12: MSB0010841 120 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22 Subject 13: MSB0010841 240 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (pre-dose) Subject 1: Placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (pre-dose) Subject 2: Placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (pre-dose) Subject 3: Placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (pre-dose) Subject 4: MSB0010841 30 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (pre-dose) Subject 5: MSB0010841 30 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (pre-dose) Subject 6: MSB0010841 30 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (pre-dose) Subject 7: MSB0010841 60 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (pre-dose) Subject 8: MSB0010841 120 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (pre-dose) Subject 9: MSB0010841 120 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (pre-dose) Subject 10: MSB0010841 120 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (pre-dose) Subject 11: MSB0010841 120 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (pre-dose) Subject 12: MSB0010841 120 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (pre-dose) Subject 13: MSB0010841 240 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 36 Subject 1: Placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data were not assessed as no sample was collected at this time point</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 36 Subject 2: Placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 36 Subject 3: Placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 36 Subject 4: MSB0010841 30 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 36 Subject 5: MSB0010841 30 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 36 Subject 6: MSB0010841 30 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 36 Subject 7: MSB0010841 60 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 36 Subject 8: MSB0010841 120 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data were not assessed as no sample was collected at this time point</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 36 Subject 9: MSB0010841 120 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 36 Subject 10: MSB0010841 120 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 36 Subject 11: MSB0010841 120 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 36 Subject 12: MSB0010841 120 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 36 Subject 13: MSB0010841 240 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43 Subject 1: Placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43 Subject 2: Placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43 Subject 3: Placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43 Subject 4: MSB0010841 30 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43 Subject 5: MSB0010841 30 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43 Subject 6: MSB0010841 30 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43 Subject 7: MSB0010841 60 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43 Subject 8: MSB0010841 120 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43 Subject 9: MSB0010841 120 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43 Subject 10: MSB0010841 120 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43 Subject 11: MSB0010841 120 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43 Subject 12: MSB0010841 120 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43 Subject 13: MSB0010841 240 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 63 Subject 1: Placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 63 Subject 2: Placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 63 Subject 3: Placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 63 Subject 4: MSB0010841 30 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 63 Subject 5: MSB0010841 30 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 63 Subject 6: MSB0010841 30 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 63 Subject 7: MSB0010841 60 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 63 Subject 8: MSB0010841 120 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 63 Subject 9: MSB0010841 120 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 63 Subject 10: MSB0010841 120 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 63 Subject 11: MSB0010841 120 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 63 Subject 12: MSB0010841 120 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 63 Subject 13: MSB0010841 240 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85 Subject 1: Placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85 Subject 2: Placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85 Subject 3: Placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85 Subject 4: MSB0010841 30 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85 Subject 5: MSB0010841 30 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85 Subject 6: MSB0010841 30 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85 Subject 7: MSB0010841 60 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85 Subject 8: MSB0010841 120 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85 Subject 9: MSB0010841 120 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85 Subject 10: MSB0010841 120 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85 Subject 11: MSB0010841 120 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85 Subject 12: MSB0010841 120 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85 Subject 13: MSB0010841 240 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Levels of Pre-existing Anti-MSB0010841 Antibody Titers</title>
        <time_frame>Pre-dose on Day 1</time_frame>
        <population>All subjects who received placebo or MSB0010841 (30 mg, 60 mg, 90 mg or 240 mg) and had positive ADA titers before and/or after study drug administration were included in the analysis population.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA Positive Subjects</title>
            <description>All subjects who received placebo or MSB0010841 (30 mg, 60 mg, 90 mg or 240 mg) and had positive ADA titers before and/or after study drug administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Levels of Pre-existing Anti-MSB0010841 Antibody Titers</title>
          <population>All subjects who received placebo or MSB0010841 (30 mg, 60 mg, 90 mg or 240 mg) and had positive ADA titers before and/or after study drug administration were included in the analysis population.</population>
          <units>log10titer</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subject 1: Placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subject 2: Placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subject 3: Placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subject 4: MSB0010841 30 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subject 5: MSB0010841 30 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subject 6: MSB0010841 30 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subject 7: MSB0010841 60 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subject 8: MSB0010841 120 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subject 9: MSB0010841 120 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subject 10: MSB0010841 120 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subject 11: MSB0010841 120 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subject 12: MSB0010841 120 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subject 13: MSB0010841 240 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>MSB0010841 Serum Concentration Over Time After First Dose</title>
        <time_frame>0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-first dose (Day 1)</time_frame>
        <population>PK analysis set included subjects who received first dose of MSB0010841 without protocol deviations affecting PK, and who provide evaluable PK data. Here “n” signifies those subjects who were evaluable for this outcome measure at the specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>MSB0010841 30 mg</title>
            <description>MSB0010841 (Anti- IL-17A/F Nanobody) was administered at a dose of 30 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>MSB0010841 60 mg</title>
            <description>MSB0010841 was administered at a dose of 60 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>MSB0010841 120 mg</title>
            <description>MSB0010841 was administered at a dose of 120 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O4">
            <title>MSB0010841 240 mg</title>
            <description>MSB0010841 was administered at a dose of 240 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>MSB0010841 Serum Concentration Over Time After First Dose</title>
          <population>PK analysis set included subjects who received first dose of MSB0010841 without protocol deviations affecting PK, and who provide evaluable PK data. Here “n” signifies those subjects who were evaluable for this outcome measure at the specified time points.</population>
          <units>nanogram/milliliter (ng/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0 hour (n=8,8,8,9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.6" spread="35.71"/>
                    <measurement group_id="O2" value="0.0" spread="0.00"/>
                    <measurement group_id="O3" value="0.0" spread="0.00"/>
                    <measurement group_id="O4" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hour (n=8,8,8,9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="907.5" spread="523.16"/>
                    <measurement group_id="O2" value="2097.1" spread="1391.43"/>
                    <measurement group_id="O3" value="2315.5" spread="787.02"/>
                    <measurement group_id="O4" value="4858.8" spread="2326.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hour (n=8,8,8,9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1793.3" spread="761.23"/>
                    <measurement group_id="O2" value="3339.6" spread="1671.29"/>
                    <measurement group_id="O3" value="4983.1" spread="1501.41"/>
                    <measurement group_id="O4" value="9780.3" spread="4698.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hour (n=8,8,8,9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2788.4" spread="895.89"/>
                    <measurement group_id="O2" value="5047.8" spread="1600.25"/>
                    <measurement group_id="O3" value="9131.3" spread="2838.02"/>
                    <measurement group_id="O4" value="15357.6" spread="5295.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>32 hour (n=8,8,8,9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3037.3" spread="820.76"/>
                    <measurement group_id="O2" value="6028.1" spread="2269.66"/>
                    <measurement group_id="O3" value="11372.4" spread="3499.37"/>
                    <measurement group_id="O4" value="17135.2" spread="6032.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>72 hour (n=8,8,7,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3190.4" spread="810.18"/>
                    <measurement group_id="O2" value="6492.9" spread="1472.29"/>
                    <measurement group_id="O3" value="11284.1" spread="2562.84"/>
                    <measurement group_id="O4" value="20536.6" spread="6716.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>96 hour (n=8,8,8,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3155.8" spread="879.56"/>
                    <measurement group_id="O2" value="6423.8" spread="1824.46"/>
                    <measurement group_id="O3" value="11790.0" spread="3319.36"/>
                    <measurement group_id="O4" value="18732.9" spread="4670.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>168 hour (n=8,8,8,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2665.5" spread="605.89"/>
                    <measurement group_id="O2" value="5179.5" spread="1126.74"/>
                    <measurement group_id="O3" value="10318.6" spread="2837.81"/>
                    <measurement group_id="O4" value="17761.9" spread="3072.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>336 hour (n=8,8,8,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1704.3" spread="429.78"/>
                    <measurement group_id="O2" value="3951.0" spread="1353.92"/>
                    <measurement group_id="O3" value="6768.4" spread="2846.24"/>
                    <measurement group_id="O4" value="11605.8" spread="2065.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>MSB0010841 Serum Concentration Over Time After Second Dose</title>
        <time_frame>0 hours (pre-dose), 24, 72, 96, 168, 336 hours post-second dose (Day 15)</time_frame>
        <population>PK analysis set included subjects who received active treatment (MSB0010841) without protocol deviations affecting PK, and who provide evaluable PK data. Here “Number of participants analyzed” signifies those subjects who were evaluable for this outcome measure at the specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>MSB0010841 30 mg</title>
            <description>MSB0010841 (Anti- IL-17A/F Nanobody) was administered at a dose of 30 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>MSB0010841 60 mg</title>
            <description>MSB0010841 was administered at a dose of 60 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>MSB0010841 120 mg</title>
            <description>MSB0010841 was administered at a dose of 120 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O4">
            <title>MSB0010841 240 mg</title>
            <description>MSB0010841 was administered at a dose of 240 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>MSB0010841 Serum Concentration Over Time After Second Dose</title>
          <population>PK analysis set included subjects who received active treatment (MSB0010841) without protocol deviations affecting PK, and who provide evaluable PK data. Here “Number of participants analyzed” signifies those subjects who were evaluable for this outcome measure at the specified time points.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1704.3" spread="429.78"/>
                    <measurement group_id="O2" value="3951.0" spread="1353.92"/>
                    <measurement group_id="O3" value="6768.4" spread="2846.24"/>
                    <measurement group_id="O4" value="11605.8" spread="2065.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3808.0" spread="980.68"/>
                    <measurement group_id="O2" value="7268.9" spread="3771.98"/>
                    <measurement group_id="O3" value="15120.6" spread="3393.84"/>
                    <measurement group_id="O4" value="27664.8" spread="9231.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>72 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4309.0" spread="1265.45"/>
                    <measurement group_id="O2" value="9095.5" spread="2115.16"/>
                    <measurement group_id="O3" value="17454.4" spread="4152.32"/>
                    <measurement group_id="O4" value="29902.4" spread="7523.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>96 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4020.5" spread="923.65"/>
                    <measurement group_id="O2" value="8514.4" spread="1849.44"/>
                    <measurement group_id="O3" value="17081.4" spread="5056.17"/>
                    <measurement group_id="O4" value="29223.5" spread="8336.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>168 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3517.8" spread="877.96"/>
                    <measurement group_id="O2" value="7180.4" spread="1705.24"/>
                    <measurement group_id="O3" value="14806.6" spread="5632.99"/>
                    <measurement group_id="O4" value="22972.5" spread="11219.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>336 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2306.5" spread="588.50"/>
                    <measurement group_id="O2" value="4492.9" spread="1398.63"/>
                    <measurement group_id="O3" value="10468.9" spread="4376.75"/>
                    <measurement group_id="O4" value="16454.5" spread="4548.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>MSB0010841 Serum Concentration Over Time After Third Dose</title>
        <time_frame>0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)</time_frame>
        <population>PK analysis set included subjects who received active treatment (MSB0010841) without protocol deviations affecting PK, and who provide evaluable PK data. Here “Number of participants analyzed” signifies those subjects who were evaluable for this outcome measure at the specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>MSB0010841 30 mg</title>
            <description>MSB0010841 (Anti- IL-17A/F Nanobody) was administered at a dose of 30 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>MSB0010841 60 mg</title>
            <description>MSB0010841 was administered at a dose of 60 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>MSB0010841 120 mg</title>
            <description>MSB0010841 was administered at a dose of 120 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O4">
            <title>MSB0010841 240 mg</title>
            <description>MSB0010841 was administered at a dose of 240 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>MSB0010841 Serum Concentration Over Time After Third Dose</title>
          <population>PK analysis set included subjects who received active treatment (MSB0010841) without protocol deviations affecting PK, and who provide evaluable PK data. Here “Number of participants analyzed” signifies those subjects who were evaluable for this outcome measure at the specified time points.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2306.5" spread="588.50"/>
                    <measurement group_id="O2" value="4492.9" spread="1398.63"/>
                    <measurement group_id="O3" value="10417.7" spread="4724.84"/>
                    <measurement group_id="O4" value="16173.6" spread="4837.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3483.9" spread="1566.88"/>
                    <measurement group_id="O2" value="6200.1" spread="1391.38"/>
                    <measurement group_id="O3" value="12725.0" spread="5573.11"/>
                    <measurement group_id="O4" value="20452.3" spread="6683.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3557.9" spread="1004.43"/>
                    <measurement group_id="O2" value="8615.5" spread="3093.46"/>
                    <measurement group_id="O3" value="13361.0" spread="5959.26"/>
                    <measurement group_id="O4" value="26051.4" spread="8770.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4533.3" spread="1178.14"/>
                    <measurement group_id="O2" value="9969.9" spread="2494.60"/>
                    <measurement group_id="O3" value="17523.1" spread="6140.31"/>
                    <measurement group_id="O4" value="33651.7" spread="11590.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>32 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4934.5" spread="1256.47"/>
                    <measurement group_id="O2" value="10762.5" spread="2377.88"/>
                    <measurement group_id="O3" value="18634.9" spread="5713.14"/>
                    <measurement group_id="O4" value="38278.4" spread="13391.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>72 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4936.0" spread="1387.50"/>
                    <measurement group_id="O2" value="10345.6" spread="4586.24"/>
                    <measurement group_id="O3" value="19813.1" spread="6381.27"/>
                    <measurement group_id="O4" value="37166.4" spread="10103.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>96 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4994.9" spread="1448.53"/>
                    <measurement group_id="O2" value="9047.6" spread="2760.25"/>
                    <measurement group_id="O3" value="18260.1" spread="6602.90"/>
                    <measurement group_id="O4" value="33909.3" spread="10219.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>168 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4368.1" spread="1201.56"/>
                    <measurement group_id="O2" value="7715.4" spread="3019.93"/>
                    <measurement group_id="O3" value="15585.3" spread="5625.65"/>
                    <measurement group_id="O4" value="31375.9" spread="6826.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>336 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2680.5" spread="859.35"/>
                    <measurement group_id="O2" value="5602.1" spread="3057.34"/>
                    <measurement group_id="O3" value="12257.6" spread="7468.85"/>
                    <measurement group_id="O4" value="20011.9" spread="6248.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>504 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1802.0" spread="505.42"/>
                    <measurement group_id="O2" value="3109.1" spread="1519.66"/>
                    <measurement group_id="O3" value="8610.6" spread="5991.68"/>
                    <measurement group_id="O4" value="12472.4" spread="4176.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>816 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="933.1" spread="376.76"/>
                    <measurement group_id="O2" value="1378.1" spread="834.66"/>
                    <measurement group_id="O3" value="4309.3" spread="4044.88"/>
                    <measurement group_id="O4" value="5064.6" spread="2070.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1056 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="464.5" spread="257.13"/>
                    <measurement group_id="O2" value="658.5" spread="391.39"/>
                    <measurement group_id="O3" value="2599.7" spread="2937.08"/>
                    <measurement group_id="O4" value="2475.9" spread="1391.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1344 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="244.8" spread="162.24"/>
                    <measurement group_id="O2" value="326.3" spread="230.87"/>
                    <measurement group_id="O3" value="1611.3" spread="2199.92"/>
                    <measurement group_id="O4" value="1345.7" spread="879.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) Post First Dose of MSB0010841</title>
        <description>Area under the serum concentration-time curve (AUC) from time zero to the last sampling time point at which the concentration is at or above lower limit of quantification (LLOQ).</description>
        <time_frame>0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-first dose (Day 1)</time_frame>
        <population>PK analysis set included subjects who received active treatment (MSB0010841) without protocol deviations affecting PK, and who provide evaluable PK data. Here “Number of participants analyzed” signifies those subjects who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>MSB0010841 30 mg</title>
            <description>MSB0010841 (Anti- IL-17A/F Nanobody) was administered at a dose of 30 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>MSB0010841 60 mg</title>
            <description>MSB0010841 was administered at a dose of 60 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>MSB0010841 120 mg</title>
            <description>MSB0010841 was administered at a dose of 120 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O4">
            <title>MSB0010841 240 mg</title>
            <description>MSB0010841 was administered at a dose of 240 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) Post First Dose of MSB0010841</title>
          <description>Area under the serum concentration-time curve (AUC) from time zero to the last sampling time point at which the concentration is at or above lower limit of quantification (LLOQ).</description>
          <population>PK analysis set included subjects who received active treatment (MSB0010841) without protocol deviations affecting PK, and who provide evaluable PK data. Here “Number of participants analyzed” signifies those subjects who were evaluable for this outcome measure.</population>
          <units>day*microgram per milliliter (day*mcg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.6" spread="28.0"/>
                    <measurement group_id="O2" value="69.3" spread="18.9"/>
                    <measurement group_id="O3" value="126.3" spread="28.5"/>
                    <measurement group_id="O4" value="216.5" spread="23.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) Post Third Dose of MSB0010841</title>
        <description>Area under the serum concentration-time curve (AUC) from time zero to the last sampling time point at which the concentration is at or above LLOQ.</description>
        <time_frame>0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)</time_frame>
        <population>PK analysis set included subjects who received active treatment (MSB0010841) without protocol deviations affecting PK, and who provide evaluable PK data. Here “Number of participants analyzed” signifies those subjects who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>MSB0010841 30 mg</title>
            <description>MSB0010841 (Anti- IL-17A/F Nanobody) was administered at a dose of 30 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>MSB0010841 60 mg</title>
            <description>MSB0010841 was administered at a dose of 60 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>MSB0010841 120 mg</title>
            <description>MSB0010841 was administered at a dose of 120 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O4">
            <title>MSB0010841 240 mg</title>
            <description>MSB0010841 was administered at a dose of 240 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) Post Third Dose of MSB0010841</title>
          <description>Area under the serum concentration-time curve (AUC) from time zero to the last sampling time point at which the concentration is at or above LLOQ.</description>
          <population>PK analysis set included subjects who received active treatment (MSB0010841) without protocol deviations affecting PK, and who provide evaluable PK data. Here “Number of participants analyzed” signifies those subjects who were evaluable for this outcome measure.</population>
          <units>day*mcg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.7" spread="41.4"/>
                    <measurement group_id="O2" value="170.3" spread="39.5"/>
                    <measurement group_id="O3" value="371.7" spread="62.0"/>
                    <measurement group_id="O4" value="663.4" spread="31.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration-Time Curve From Time Zero up to Time Tau (AUCtau) Post First Dose of MSB0010841</title>
        <description>Area under the concentration-time curve from time zero up to time Tau, where Tau is the dosing interval (336 hours).</description>
        <time_frame>0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-first dose (Day 1)</time_frame>
        <population>PK analysis set included subjects who received active treatment (MSB0010841) without protocol deviations affecting PK, and who provide evaluable PK data. Here “Number of participants analyzed” signifies those subjects who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>MSB0010841 30 mg</title>
            <description>MSB0010841 (Anti- IL-17A/F Nanobody) was administered at a dose of 30 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>MSB0010841 60 mg</title>
            <description>MSB0010841 was administered at a dose of 60 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>MSB0010841 120 mg</title>
            <description>MSB0010841 was administered at a dose of 120 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O4">
            <title>MSB0010841 240 mg</title>
            <description>MSB0010841 was administered at a dose of 240 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-Time Curve From Time Zero up to Time Tau (AUCtau) Post First Dose of MSB0010841</title>
          <description>Area under the concentration-time curve from time zero up to time Tau, where Tau is the dosing interval (336 hours).</description>
          <population>PK analysis set included subjects who received active treatment (MSB0010841) without protocol deviations affecting PK, and who provide evaluable PK data. Here “Number of participants analyzed” signifies those subjects who were evaluable for this outcome measure.</population>
          <units>day*mcg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.4" spread="31.2"/>
                    <measurement group_id="O2" value="68.3" spread="16.4"/>
                    <measurement group_id="O3" value="114.6" spread="24.2"/>
                    <measurement group_id="O4" value="222.2" spread="19.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration-Time Curve From Time Zero up to Time Tau (AUCtau) Post Third Dose of MSB0010841</title>
        <description>Area under the concentration-time curve from time zero up to time Tau, where Tau is the dosing interval (336 hours).</description>
        <time_frame>0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-third dose (Day 29)</time_frame>
        <population>PK analysis set included subjects who received active treatment (MSB0010841) without protocol deviations affecting PK, and who provide evaluable PK data. Here “Number of participants analyzed” signifies those subjects who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>MSB0010841 30 mg</title>
            <description>MSB0010841 (Anti- IL-17A/F Nanobody) was administered at a dose of 30 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>MSB0010841 60 mg</title>
            <description>MSB0010841 was administered at a dose of 60 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>MSB0010841 120 mg</title>
            <description>MSB0010841 was administered at a dose of 120 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O4">
            <title>MSB0010841 240 mg</title>
            <description>MSB0010841 was administered at a dose of 240 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-Time Curve From Time Zero up to Time Tau (AUCtau) Post Third Dose of MSB0010841</title>
          <description>Area under the concentration-time curve from time zero up to time Tau, where Tau is the dosing interval (336 hours).</description>
          <population>PK analysis set included subjects who received active treatment (MSB0010841) without protocol deviations affecting PK, and who provide evaluable PK data. Here “Number of participants analyzed” signifies those subjects who were evaluable for this outcome measure.</population>
          <units>day*mcg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.2" spread="36.3"/>
                    <measurement group_id="O2" value="104.1" spread="33.9"/>
                    <measurement group_id="O3" value="203.2" spread="43.6"/>
                    <measurement group_id="O4" value="397.6" spread="27.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration-time Curve From Time Zero to Infinity (AUC 0-inf) Post Third Dose of MSB0010841</title>
        <description>Area under the serum concentration-time curve from time zero to infinity (AUC0-inf). AUC0-infcalculated as AUC0-t + AUCextra. AUCextra represents the extrapolated part of AUC0-inf calculated by Clast calc/λz, where Clast calc is the calculated concentration at the last sampling time point at which the measured concentration is at or above LLOQ and λz is the terminal rate constant determined from the terminal slope of the log transformed concentration curve using linear regression on terminal data points of the curve.</description>
        <time_frame>0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)</time_frame>
        <population>PK analysis set included subjects who received active treatment (MSB0010841) without protocol deviations affecting PK, and who provide evaluable PK data. Here “Number of participants analyzed” signifies those subjects who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>MSB0010841 30 mg</title>
            <description>MSB0010841 (Anti- IL-17A/F Nanobody) was administered at a dose of 30 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>MSB0010841 60 mg</title>
            <description>MSB0010841 was administered at a dose of 60 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>MSB0010841 120 mg</title>
            <description>MSB0010841 was administered at a dose of 120 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O4">
            <title>MSB0010841 240 mg</title>
            <description>MSB0010841 was administered at a dose of 240 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve From Time Zero to Infinity (AUC 0-inf) Post Third Dose of MSB0010841</title>
          <description>Area under the serum concentration-time curve from time zero to infinity (AUC0-inf). AUC0-infcalculated as AUC0-t + AUCextra. AUCextra represents the extrapolated part of AUC0-inf calculated by Clast calc/λz, where Clast calc is the calculated concentration at the last sampling time point at which the measured concentration is at or above LLOQ and λz is the terminal rate constant determined from the terminal slope of the log transformed concentration curve using linear regression on terminal data points of the curve.</description>
          <population>PK analysis set included subjects who received active treatment (MSB0010841) without protocol deviations affecting PK, and who provide evaluable PK data. Here “Number of participants analyzed” signifies those subjects who were evaluable for this outcome measure.</population>
          <units>day*ug/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.6" spread="42.2"/>
                    <measurement group_id="O2" value="174.9" spread="39.9"/>
                    <measurement group_id="O3" value="392.6" spread="68.8"/>
                    <measurement group_id="O4" value="680.9" spread="32.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Observed Serum Concentration Immediately Before First Dose (Cpre) of MSB0010841</title>
        <description>The observed serum concentration immediately before the first dose.</description>
        <time_frame>Pre-dose (0 hours) on Day 1</time_frame>
        <population>PK analysis set included subjects who received active treatment (MSB0010841) without protocol deviations affecting PK, and who provide evaluable PK data. Here “Number of participants analyzed” signifies those subjects who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>MSB0010841 30 mg</title>
            <description>MSB0010841 (Anti- IL-17A/F Nanobody) was administered at a dose of 30 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>MSB0010841 60 mg</title>
            <description>MSB0010841 was administered at a dose of 60 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>MSB0010841 120 mg</title>
            <description>MSB0010841 was administered at a dose of 120 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O4">
            <title>MSB0010841 240 mg</title>
            <description>MSB0010841 was administered at a dose of 240 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Observed Serum Concentration Immediately Before First Dose (Cpre) of MSB0010841</title>
          <description>The observed serum concentration immediately before the first dose.</description>
          <population>PK analysis set included subjects who received active treatment (MSB0010841) without protocol deviations affecting PK, and who provide evaluable PK data. Here “Number of participants analyzed” signifies those subjects who were evaluable for this outcome measure.</population>
          <units>mcg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.036"/>
                    <measurement group_id="O2" value="0.00" spread="0.000"/>
                    <measurement group_id="O3" value="0.00" spread="0.000"/>
                    <measurement group_id="O4" value="0.00" spread="0.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Observed Serum Concentration Immediately Before Third Dose (Cpre) of MSB0010841</title>
        <description>The observed serum concentration immediately before the third dose.</description>
        <time_frame>Pre-dose (0 hours) on Day 29</time_frame>
        <population>PK analysis set included subjects who received active treatment (MSB0010841) without protocol deviations affecting PK, and who provide evaluable PK data. Here “Number of participants analyzed” signifies those subjects who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>MSB0010841 30 mg</title>
            <description>MSB0010841 (Anti- IL-17A/F Nanobody) was administered at a dose of 30 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>MSB0010841 60 mg</title>
            <description>MSB0010841 was administered at a dose of 60 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>MSB0010841 120 mg</title>
            <description>MSB0010841 was administered at a dose of 120 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O4">
            <title>MSB0010841 240 mg</title>
            <description>MSB0010841 was administered at a dose of 240 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Observed Serum Concentration Immediately Before Third Dose (Cpre) of MSB0010841</title>
          <description>The observed serum concentration immediately before the third dose.</description>
          <population>PK analysis set included subjects who received active treatment (MSB0010841) without protocol deviations affecting PK, and who provide evaluable PK data. Here “Number of participants analyzed” signifies those subjects who were evaluable for this outcome measure.</population>
          <units>mcg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.31" spread="0.59"/>
                    <measurement group_id="O2" value="4.49" spread="1.40"/>
                    <measurement group_id="O3" value="10.42" spread="4.72"/>
                    <measurement group_id="O4" value="16.17" spread="4.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Minimum Concentration Observed (Cmin) During First Dosing Interval of MSB0010841</title>
        <description>The observed minimum serum concentration determined directly from the serum concentration-time profile of each subject.</description>
        <time_frame>0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-first dose (Day 1)</time_frame>
        <population>PK analysis set included subjects who received active treatment (MSB0010841) without protocol deviations affecting PK, and who provide evaluable PK data. Here “Number of participants analyzed” signifies those subjects who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>MSB0010841 30 mg</title>
            <description>MSB0010841 (Anti- IL-17A/F Nanobody) was administered at a dose of 30 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>MSB0010841 60 mg</title>
            <description>MSB0010841 was administered at a dose of 60 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>MSB0010841 120 mg</title>
            <description>MSB0010841 was administered at a dose of 120 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O4">
            <title>MSB0010841 240 mg</title>
            <description>MSB0010841 was administered at a dose of 240 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Minimum Concentration Observed (Cmin) During First Dosing Interval of MSB0010841</title>
          <description>The observed minimum serum concentration determined directly from the serum concentration-time profile of each subject.</description>
          <population>PK analysis set included subjects who received active treatment (MSB0010841) without protocol deviations affecting PK, and who provide evaluable PK data. Here “Number of participants analyzed” signifies those subjects who were evaluable for this outcome measure.</population>
          <units>mcg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.036"/>
                    <measurement group_id="O2" value="0.00" spread="0.000"/>
                    <measurement group_id="O3" value="0.00" spread="0.000"/>
                    <measurement group_id="O4" value="0.00" spread="0.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Minimum Concentration Observed (Cmin) During Third Dosing Interval of MSB0010841</title>
        <description>The observed minimum serum concentration determined directly from the serum concentration-time profile of each subject.</description>
        <time_frame>0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)</time_frame>
        <population>PK analysis set included subjects who received active treatment (MSB0010841) without protocol deviations affecting PK, and who provide evaluable PK data. Here “Number of participants analyzed” signifies those subjects who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>MSB0010841 30 mg</title>
            <description>MSB0010841 (Anti- IL-17A/F Nanobody) was administered at a dose of 30 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>MSB0010841 60 mg</title>
            <description>MSB0010841 was administered at a dose of 60 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>MSB0010841 120 mg</title>
            <description>MSB0010841 was administered at a dose of 120 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O4">
            <title>MSB0010841 240 mg</title>
            <description>MSB0010841 was administered at a dose of 240 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Minimum Concentration Observed (Cmin) During Third Dosing Interval of MSB0010841</title>
          <description>The observed minimum serum concentration determined directly from the serum concentration-time profile of each subject.</description>
          <population>PK analysis set included subjects who received active treatment (MSB0010841) without protocol deviations affecting PK, and who provide evaluable PK data. Here “Number of participants analyzed” signifies those subjects who were evaluable for this outcome measure.</population>
          <units>mcg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.30" spread="0.60"/>
                    <measurement group_id="O2" value="4.34" spread="1.40"/>
                    <measurement group_id="O3" value="10.03" spread="4.95"/>
                    <measurement group_id="O4" value="16.17" spread="4.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Concentration Observed (Cmax) Post First Dose of MSB0010841</title>
        <time_frame>0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-first dose (Day 1)</time_frame>
        <population>PK analysis set included subjects who received active treatment (MSB0010841) without protocol deviations affecting PK, and who provide evaluable PK data. Here “Number of participants analyzed” signifies those subjects who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>MSB0010841 30 mg</title>
            <description>MSB0010841 (Anti- IL-17A/F Nanobody) was administered at a dose of 30 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>MSB0010841 60 mg</title>
            <description>MSB0010841 was administered at a dose of 60 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>MSB0010841 120 mg</title>
            <description>MSB0010841 was administered at a dose of 120 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O4">
            <title>MSB0010841 240 mg</title>
            <description>MSB0010841 was administered at a dose of 240 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Concentration Observed (Cmax) Post First Dose of MSB0010841</title>
          <population>PK analysis set included subjects who received active treatment (MSB0010841) without protocol deviations affecting PK, and who provide evaluable PK data. Here “Number of participants analyzed” signifies those subjects who were evaluable for this outcome measure.</population>
          <units>mcg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="28.4"/>
                    <measurement group_id="O2" value="7.4" spread="22.9"/>
                    <measurement group_id="O3" value="12.5" spread="25.6"/>
                    <measurement group_id="O4" value="20.8" spread="30.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Concentration Observed (Cmax) Post Third Dose of MSB0010841</title>
        <time_frame>0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)</time_frame>
        <population>PK analysis set included subjects who received active treatment (MSB0010841) without protocol deviations affecting PK, and who provide evaluable PK data. Here “Number of participants analyzed” signifies those subjects who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>MSB0010841 30 mg</title>
            <description>MSB0010841 (Anti- IL-17A/F Nanobody) was administered at a dose of 30 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>MSB0010841 60 mg</title>
            <description>MSB0010841 was administered at a dose of 60 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>MSB0010841 120 mg</title>
            <description>MSB0010841 was administered at a dose of 120 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O4">
            <title>MSB0010841 240 mg</title>
            <description>MSB0010841 was administered at a dose of 240 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Concentration Observed (Cmax) Post Third Dose of MSB0010841</title>
          <population>PK analysis set included subjects who received active treatment (MSB0010841) without protocol deviations affecting PK, and who provide evaluable PK data. Here “Number of participants analyzed” signifies those subjects who were evaluable for this outcome measure.</population>
          <units>mcg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.14" spread="34.5"/>
                    <measurement group_id="O2" value="11.32" spread="29.7"/>
                    <measurement group_id="O3" value="19.74" spread="31.3"/>
                    <measurement group_id="O4" value="37.93" spread="32.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Average Concentration (Cav) Post First Dose of MSB0010841</title>
        <description>Cav was calculated by AUCtau/tau. Where tau is the dosing interval (336 hours).</description>
        <time_frame>0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-first dose (Day 1)</time_frame>
        <population>PK analysis set included subjects who received active treatment (MSB0010841) without protocol deviations affecting PK, and who provide evaluable PK data. Here “Number of participants analyzed” signifies those subjects who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>MSB0010841 30 mg</title>
            <description>MSB0010841 (Anti- IL-17A/F Nanobody) was administered at a dose of 30 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>MSB0010841 60 mg</title>
            <description>MSB0010841 was administered at a dose of 60 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>MSB0010841 120 mg</title>
            <description>MSB0010841 was administered at a dose of 120 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O4">
            <title>MSB0010841 240 mg</title>
            <description>MSB0010841 was administered at a dose of 240 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Concentration (Cav) Post First Dose of MSB0010841</title>
          <description>Cav was calculated by AUCtau/tau. Where tau is the dosing interval (336 hours).</description>
          <population>PK analysis set included subjects who received active treatment (MSB0010841) without protocol deviations affecting PK, and who provide evaluable PK data. Here “Number of participants analyzed” signifies those subjects who were evaluable for this outcome measure.</population>
          <units>mcg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.315" spread="31.2"/>
                    <measurement group_id="O2" value="4.881" spread="16.4"/>
                    <measurement group_id="O3" value="8.187" spread="24.2"/>
                    <measurement group_id="O4" value="15.868" spread="19.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Average Concentration (Cav) Post Third Dose of MSB0010841</title>
        <description>Cav was calculated by AUCtau/tau. Where tau is the dosing interval (336 hours).</description>
        <time_frame>0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)</time_frame>
        <population>PK analysis set included subjects who received active treatment (MSB0010841) without protocol deviations affecting PK, and who provide evaluable PK data. Here “Number of participants analyzed” signifies those subjects who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>MSB0010841 30 mg</title>
            <description>MSB0010841 (Anti- IL-17A/F Nanobody) was administered at a dose of 30 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>MSB0010841 60 mg</title>
            <description>MSB0010841 was administered at a dose of 60 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>MSB0010841 120 mg</title>
            <description>MSB0010841 was administered at a dose of 120 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O4">
            <title>MSB0010841 240 mg</title>
            <description>MSB0010841 was administered at a dose of 240 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Concentration (Cav) Post Third Dose of MSB0010841</title>
          <description>Cav was calculated by AUCtau/tau. Where tau is the dosing interval (336 hours).</description>
          <population>PK analysis set included subjects who received active treatment (MSB0010841) without protocol deviations affecting PK, and who provide evaluable PK data. Here “Number of participants analyzed” signifies those subjects who were evaluable for this outcome measure.</population>
          <units>mcg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.87" spread="36.3"/>
                    <measurement group_id="O2" value="7.44" spread="33.9"/>
                    <measurement group_id="O3" value="14.51" spread="43.6"/>
                    <measurement group_id="O4" value="28.40" spread="27.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Residence Time (MRT0-t) Post First Dose of MSB0010841</title>
        <description>MRT is the average time at which the number of absorbed molecules reside in the body, after single-dose administration, and calculated as AUMC(0-t)/AUC(0-t) where AUMC(0-t) is area under the plasma concentration-time first moment curve from time zero to time t (336 hours) and AUC(0-t) is the area under the plasma concentration-time curve from time zero to tome t (336 hours).</description>
        <time_frame>0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-first dose (Day 1)</time_frame>
        <population>PK analysis set included subjects who received active treatment (MSB0010841) without protocol deviations affecting PK, and who provide evaluable PK data. Here “Number of participants analyzed” signifies those subjects who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>MSB0010841 30 mg</title>
            <description>MSB0010841 (Anti- IL-17A/F Nanobody) was administered at a dose of 30 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>MSB0010841 60 mg</title>
            <description>MSB0010841 was administered at a dose of 60 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>MSB0010841 120 mg</title>
            <description>MSB0010841 was administered at a dose of 120 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O4">
            <title>MSB0010841 240 mg</title>
            <description>MSB0010841 was administered at a dose of 240 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Residence Time (MRT0-t) Post First Dose of MSB0010841</title>
          <description>MRT is the average time at which the number of absorbed molecules reside in the body, after single-dose administration, and calculated as AUMC(0-t)/AUC(0-t) where AUMC(0-t) is area under the plasma concentration-time first moment curve from time zero to time t (336 hours) and AUC(0-t) is the area under the plasma concentration-time curve from time zero to tome t (336 hours).</description>
          <population>PK analysis set included subjects who received active treatment (MSB0010841) without protocol deviations affecting PK, and who provide evaluable PK data. Here “Number of participants analyzed” signifies those subjects who were evaluable for this outcome measure.</population>
          <units>day</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.528" spread="3.6"/>
                    <measurement group_id="O2" value="6.691" spread="8.1"/>
                    <measurement group_id="O3" value="6.638" spread="5.7"/>
                    <measurement group_id="O4" value="6.771" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Residence Time (MRT0-t) Post Third Dose of MSB0010841</title>
        <description>MRT is the average time at which the number of absorbed molecules reside in the body, after single-dose administration, and calculated as AUMC(0-t)/AUC(0-t) where AUMC(0-t) is area under the plasma concentration-time first moment curve from time zero to time t (336 hours) and AUC(0-t) is the area under the plasma concentration-time curve from time zero to tome t (336 hours).</description>
        <time_frame>0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-third dose (Day 29)</time_frame>
        <population>PK analysis set included subjects who received active treatment (MSB0010841) without protocol deviations affecting PK, and who provide evaluable PK data. Here “Number of participants analyzed” signifies those subjects who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>MSB0010841 30 mg</title>
            <description>MSB0010841 (Anti- IL-17A/F Nanobody) was administered at a dose of 30 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>MSB0010841 60 mg</title>
            <description>MSB0010841 was administered at a dose of 60 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>MSB0010841 120 mg</title>
            <description>MSB0010841 was administered at a dose of 120 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O4">
            <title>MSB0010841 240 mg</title>
            <description>MSB0010841 was administered at a dose of 240 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Residence Time (MRT0-t) Post Third Dose of MSB0010841</title>
          <description>MRT is the average time at which the number of absorbed molecules reside in the body, after single-dose administration, and calculated as AUMC(0-t)/AUC(0-t) where AUMC(0-t) is area under the plasma concentration-time first moment curve from time zero to time t (336 hours) and AUC(0-t) is the area under the plasma concentration-time curve from time zero to tome t (336 hours).</description>
          <population>PK analysis set included subjects who received active treatment (MSB0010841) without protocol deviations affecting PK, and who provide evaluable PK data. Here “Number of participants analyzed” signifies those subjects who were evaluable for this outcome measure.</population>
          <units>day</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.57" spread="11.2"/>
                    <measurement group_id="O2" value="15.68" spread="16.3"/>
                    <measurement group_id="O3" value="19.26" spread="32.0"/>
                    <measurement group_id="O4" value="16.38" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Residence Time of Drug in the Body From Time Zero Extrapolated to Infinity (MRT(0-inf) Post Third Dose of MSB0010841</title>
        <description>Mean residence time of drug in the body from time zero extrapolated to infinity, based on the last predicted concentration at tlast.</description>
        <time_frame>0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)</time_frame>
        <population>PK analysis set included subjects who received active treatment (MSB0010841) without protocol deviations affecting PK, and who provide evaluable PK data. Here “Number of participants analyzed” signifies those subjects who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>MSB0010841 30 mg</title>
            <description>MSB0010841(Anti- IL-17A/F Nanobody) was administered at a dose of 30 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>MSB0010841 60 mg</title>
            <description>MSB0010841 was administered at a dose of 60 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>MSB0010841 120 mg</title>
            <description>MSB0010841 was administered at a dose of 120 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O4">
            <title>MSB0010841 240 mg</title>
            <description>MSB0010841 was administered at a dose of 240 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Residence Time of Drug in the Body From Time Zero Extrapolated to Infinity (MRT(0-inf) Post Third Dose of MSB0010841</title>
          <description>Mean residence time of drug in the body from time zero extrapolated to infinity, based on the last predicted concentration at tlast.</description>
          <population>PK analysis set included subjects who received active treatment (MSB0010841) without protocol deviations affecting PK, and who provide evaluable PK data. Here “Number of participants analyzed” signifies those subjects who were evaluable for this outcome measure.</population>
          <units>day</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.57" spread="11.2"/>
                    <measurement group_id="O2" value="15.68" spread="16.3"/>
                    <measurement group_id="O3" value="19.26" spread="32.0"/>
                    <measurement group_id="O4" value="16.38" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Reach Maximum Observed Concentration (Tmax) Post First Dose of MSB0010841</title>
        <time_frame>0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-first dose (Day 1)</time_frame>
        <population>PK analysis set included subjects who received active treatment (MSB0010841) without protocol deviations affecting PK, and who provide evaluable PK data. Here “Number of participants analyzed” signifies those subjects who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>MSB0010841 30 mg</title>
            <description>MSB0010841(Anti- IL-17A/F Nanobody) was administered at a dose of 30 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>MSB0010841 60 mg</title>
            <description>MSB0010841 was administered at a dose of 60 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>MSB0010841 120 mg</title>
            <description>MSB0010841 was administered at a dose of 120 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O4">
            <title>MSB0010841 240 mg</title>
            <description>MSB0010841 was administered at a dose of 240 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Observed Concentration (Tmax) Post First Dose of MSB0010841</title>
          <population>PK analysis set included subjects who received active treatment (MSB0010841) without protocol deviations affecting PK, and who provide evaluable PK data. Here “Number of participants analyzed” signifies those subjects who were evaluable for this outcome measure.</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.39" lower_limit="23.9" upper_limit="97.4"/>
                    <measurement group_id="O2" value="71.68" lower_limit="24.0" upper_limit="335.8"/>
                    <measurement group_id="O3" value="52.00" lower_limit="32.0" upper_limit="96.2"/>
                    <measurement group_id="O4" value="72.23" lower_limit="72.0" upper_limit="168.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Maximum Observed Concentration (Tmax) Post Second Dose of MSB0010841</title>
        <time_frame>0 hours (pre-dose), 24, 72, 96, 168, 336 hours post-second dose (Day 15)</time_frame>
        <population>PK analysis set included subjects who received active treatment (MSB0010841) without protocol deviations affecting PK, and who provide evaluable PK data. Here “Number of participants analyzed” signifies those subjects who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>MSB0010841 30 mg</title>
            <description>MSB0010841(Anti- IL-17A/F Nanobody) was administered at a dose of 30 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>MSB0010841 60 mg</title>
            <description>MSB0010841 was administered at a dose of 60 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>MSB0010841 120 mg</title>
            <description>MSB0010841 was administered at a dose of 120 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O4">
            <title>MSB0010841 240 mg</title>
            <description>MSB0010841 was administered at a dose of 240 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Observed Concentration (Tmax) Post Second Dose of MSB0010841</title>
          <population>PK analysis set included subjects who received active treatment (MSB0010841) without protocol deviations affecting PK, and who provide evaluable PK data. Here “Number of participants analyzed” signifies those subjects who were evaluable for this outcome measure.</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.2" lower_limit="72.0" upper_limit="97.5"/>
                    <measurement group_id="O2" value="72.0" lower_limit="24.1" upper_limit="96.6"/>
                    <measurement group_id="O3" value="83.4" lower_limit="71.8" upper_limit="168.0"/>
                    <measurement group_id="O4" value="72.0" lower_limit="24.0" upper_limit="168.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Reach Maximum Observed Concentration (Tmax) Post Third Dose of MSB0010841</title>
        <time_frame>0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)</time_frame>
        <population>PK analysis set included subjects who received active treatment (MSB0010841) without protocol deviations affecting PK, and who provide evaluable PK data. Here “Number of participants analyzed” signifies those subjects who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>MSB0010841 30 mg</title>
            <description>MSB0010841(Anti- IL-17A/F Nanobody) was administered at a dose of 30 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>MSB0010841 60 mg</title>
            <description>MSB0010841 was administered at a dose of 60 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>MSB0010841 120 mg</title>
            <description>MSB0010841 was administered at a dose of 120 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O4">
            <title>MSB0010841 240 mg</title>
            <description>MSB0010841 was administered at a dose of 240 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Observed Concentration (Tmax) Post Third Dose of MSB0010841</title>
          <population>PK analysis set included subjects who received active treatment (MSB0010841) without protocol deviations affecting PK, and who provide evaluable PK data. Here “Number of participants analyzed” signifies those subjects who were evaluable for this outcome measure.</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.5" lower_limit="6.0" upper_limit="95.8"/>
                    <measurement group_id="O2" value="31.0" lower_limit="12.0" upper_limit="72.4"/>
                    <measurement group_id="O3" value="72.0" lower_limit="31.8" upper_limit="72.5"/>
                    <measurement group_id="O4" value="72.0" lower_limit="31.1" upper_limit="168.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Terminal Half-life (t1/2) Post Third Dose of MSB0010841</title>
        <description>Terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life is calculated by dividing the natural logarithm to the base e (Log e) multiplied by (*) 2/ λz, where ‘λz’ is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.</description>
        <time_frame>0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)</time_frame>
        <population>PK analysis set included subjects who received active treatment (MSB0010841) without protocol deviations affecting PK, and who provide evaluable PK data. Here “Number of participants analyzed” signifies those subjects who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>MSB0010841 30 mg</title>
            <description>MSB0010841(Anti- IL-17A/F Nanobody) was administered at a dose of 30 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>MSB0010841 60 mg</title>
            <description>MSB0010841 was administered at a dose of 60 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>MSB0010841 120 mg</title>
            <description>MSB0010841 was administered at a dose of 120 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O4">
            <title>MSB0010841 240 mg</title>
            <description>MSB0010841 was administered at a dose of 240 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Terminal Half-life (t1/2) Post Third Dose of MSB0010841</title>
          <description>Terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life is calculated by dividing the natural logarithm to the base e (Log e) multiplied by (*) 2/ λz, where ‘λz’ is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.</description>
          <population>PK analysis set included subjects who received active treatment (MSB0010841) without protocol deviations affecting PK, and who provide evaluable PK data. Here “Number of participants analyzed” signifies those subjects who were evaluable for this outcome measure.</population>
          <units>day</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.63" spread="17.3"/>
                    <measurement group_id="O2" value="10.50" spread="18.9"/>
                    <measurement group_id="O3" value="12.19" spread="27.9"/>
                    <measurement group_id="O4" value="10.25" spread="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Terminal Rate Constant (λz) Post Third Dose of MSB0010841</title>
        <description>Terminal rate constant was determined from the terminal slope of the logtransformed concentration curve using linear regression on terminal data points of the curve</description>
        <time_frame>0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)</time_frame>
        <population>PK analysis set included subjects who received active treatment (MSB0010841) without protocol deviations affecting PK, and who provide evaluable PK data. Here “Number of participants analyzed” signifies those subjects who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>MSB0010841 30 mg</title>
            <description>MSB0010841(Anti- IL-17A/F Nanobody) was administered at a dose of 30 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>MSB0010841 60 mg</title>
            <description>MSB0010841 was administered at a dose of 60 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>MSB0010841 120 mg</title>
            <description>MSB0010841 was administered at a dose of 120 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O4">
            <title>MSB0010841 240 mg</title>
            <description>MSB0010841 was administered at a dose of 240 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Rate Constant (λz) Post Third Dose of MSB0010841</title>
          <description>Terminal rate constant was determined from the terminal slope of the logtransformed concentration curve using linear regression on terminal data points of the curve</description>
          <population>PK analysis set included subjects who received active treatment (MSB0010841) without protocol deviations affecting PK, and who provide evaluable PK data. Here “Number of participants analyzed” signifies those subjects who were evaluable for this outcome measure.</population>
          <units>1/hour</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="17.3"/>
                    <measurement group_id="O2" value="0.00" spread="18.9"/>
                    <measurement group_id="O3" value="0.00" spread="27.9"/>
                    <measurement group_id="O4" value="0.00" spread="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Clearance (CL/f) Post Third Dose of MSB0010841</title>
        <description>Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent clearance after oral dose (CL/f) is influenced by the fraction absorbed.</description>
        <time_frame>0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)</time_frame>
        <population>PK analysis set included subjects who received active treatment (MSB0010841) without protocol deviations affecting PK, and who provide evaluable PK data. Here “Number of participants analyzed” signifies those subjects who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>MSB0010841 30 mg</title>
            <description>MSB0010841(Anti- IL-17A/F Nanobody) was administered at a dose of 30 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>MSB0010841 60 mg</title>
            <description>MSB0010841 was administered at a dose of 60 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>MSB0010841 120 mg</title>
            <description>MSB0010841 was administered at a dose of 120 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O4">
            <title>MSB0010841 240 mg</title>
            <description>MSB0010841 was administered at a dose of 240 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Clearance (CL/f) Post Third Dose of MSB0010841</title>
          <description>Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent clearance after oral dose (CL/f) is influenced by the fraction absorbed.</description>
          <population>PK analysis set included subjects who received active treatment (MSB0010841) without protocol deviations affecting PK, and who provide evaluable PK data. Here “Number of participants analyzed” signifies those subjects who were evaluable for this outcome measure.</population>
          <units>L/day</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.55" spread="36.3"/>
                    <measurement group_id="O2" value="0.58" spread="33.9"/>
                    <measurement group_id="O3" value="0.59" spread="43.6"/>
                    <measurement group_id="O4" value="0.60" spread="27.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Volume of Distribution During Terminal Phase (Vz/f) Post Third Dose of MSB0010841</title>
        <description>Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. Apparent volume of distribution during the terminal phase, calculated as Vz = Dose/AUC0-inf multiplied by elimination rate constant [λz]) following first dose and Dose/(AUCtau multiplied by λz) after third dose.</description>
        <time_frame>0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)</time_frame>
        <population>PK analysis set included subjects who received active treatment (MSB0010841) without protocol deviations affecting PK, and who provide evaluable PK data. Here &quot;Number of subjects analyzed&quot; signifies those subjects who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>MSB0010841 30 mg</title>
            <description>MSB0010841(Anti- IL-17A/F Nanobody) was administered at a dose of 30 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>MSB0010841 60 mg</title>
            <description>MSB0010841 was administered at a dose of 60 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>MSB0010841 120 mg</title>
            <description>MSB0010841 was administered at a dose of 120 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O4">
            <title>MSB0010841 240 mg</title>
            <description>MSB0010841 was administered at a dose of 240 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Volume of Distribution During Terminal Phase (Vz/f) Post Third Dose of MSB0010841</title>
          <description>Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. Apparent volume of distribution during the terminal phase, calculated as Vz = Dose/AUC0-inf multiplied by elimination rate constant [λz]) following first dose and Dose/(AUCtau multiplied by λz) after third dose.</description>
          <population>PK analysis set included subjects who received active treatment (MSB0010841) without protocol deviations affecting PK, and who provide evaluable PK data. Here &quot;Number of subjects analyzed&quot; signifies those subjects who were evaluable for this outcome measure.</population>
          <units>Liters</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.49" spread="27.0"/>
                    <measurement group_id="O2" value="8.73" spread="38.6"/>
                    <measurement group_id="O3" value="10.39" spread="21.9"/>
                    <measurement group_id="O4" value="8.92" spread="18.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage Peak-Trough Fluctuation (PTF) Post First Dose of MSB0010841</title>
        <description>The peak trough fluctuation within one dosing interval, calculated as PTF (%) = ([Cmax - Cmin]/Cav ) multiplied by 100</description>
        <time_frame>0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-first dose (Day 1)</time_frame>
        <population>PK analysis set included subjects who received active treatment (MSB0010841) without protocol deviations affecting PK, and who provide evaluable PK data. Here &quot;Number of subjects analyzed&quot; signifies those subjects who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>MSB0010841 30 mg</title>
            <description>MSB0010841(Anti- IL-17A/F Nanobody) was administered at a dose of 30 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>MSB0010841 60 mg</title>
            <description>MSB0010841 was administered at a dose of 60 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>MSB0010841 120 mg</title>
            <description>MSB0010841 was administered at a dose of 120 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O4">
            <title>MSB0010841 240 mg</title>
            <description>MSB0010841 was administered at a dose of 240 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Peak-Trough Fluctuation (PTF) Post First Dose of MSB0010841</title>
          <description>The peak trough fluctuation within one dosing interval, calculated as PTF (%) = ([Cmax - Cmin]/Cav ) multiplied by 100</description>
          <population>PK analysis set included subjects who received active treatment (MSB0010841) without protocol deviations affecting PK, and who provide evaluable PK data. Here &quot;Number of subjects analyzed&quot; signifies those subjects who were evaluable for this outcome measure.</population>
          <units>percentage fluctuation</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140.28" spread="3.9"/>
                    <measurement group_id="O2" value="152.47" spread="20.4"/>
                    <measurement group_id="O3" value="144.37" spread="13.0"/>
                    <measurement group_id="O4" value="135.89" spread="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage Peak-Trough Fluctuation (PTF) Post Third Dose of MSB0010841</title>
        <description>The peak trough fluctuation within one dosing interval, calculated as PTF (%) = ([Cmax - Cmin]/Cav ) multiplied by 100</description>
        <time_frame>0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)</time_frame>
        <population>PK analysis set included subjects who received active treatment (MSB0010841) without protocol deviations affecting PK, and who provide evaluable PK data. Here &quot;Number of subjects analyzed&quot; signifies those subjects who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>MSB0010841 30 mg</title>
            <description>MSB0010841(Anti- IL-17A/F Nanobody) was administered at a dose of 30 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>MSB0010841 60 mg</title>
            <description>MSB0010841 was administered at a dose of 60 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>MSB0010841 120 mg</title>
            <description>MSB0010841 was administered at a dose of 120 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O4">
            <title>MSB0010841 240 mg</title>
            <description>MSB0010841 was administered at a dose of 240 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Peak-Trough Fluctuation (PTF) Post Third Dose of MSB0010841</title>
          <description>The peak trough fluctuation within one dosing interval, calculated as PTF (%) = ([Cmax - Cmin]/Cav ) multiplied by 100</description>
          <population>PK analysis set included subjects who received active treatment (MSB0010841) without protocol deviations affecting PK, and who provide evaluable PK data. Here &quot;Number of subjects analyzed&quot; signifies those subjects who were evaluable for this outcome measure.</population>
          <units>percentage fluctuation</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.26" spread="8.5"/>
                    <measurement group_id="O2" value="95.65" spread="18.9"/>
                    <measurement group_id="O3" value="71.17" spread="33.1"/>
                    <measurement group_id="O4" value="76.03" spread="28.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Accumulation Ratio of Cmax (Racc (Cmax))</title>
        <description>Accumulation ratio for Cmax was calculated as Cmax, after third dose / Cmax, after first dose.</description>
        <time_frame>0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-first dose (Day 1) and 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)</time_frame>
        <population>PK analysis set included subjects who received active treatment (MSB0010841) without protocol deviations affecting PK, and who provide evaluable PK data. Here “Number of participants analyzed” signifies those subjects who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>MSB0010841 30 mg</title>
            <description>MSB0010841(Anti- IL-17A/F Nanobody) was administered at a dose of 30 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>MSB0010841 60 mg</title>
            <description>MSB0010841 was administered at a dose of 60 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>MSB0010841 120 mg</title>
            <description>MSB0010841 was administered at a dose of 120 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O4">
            <title>MSB0010841 240 mg</title>
            <description>MSB0010841 was administered at a dose of 240 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Accumulation Ratio of Cmax (Racc (Cmax))</title>
          <description>Accumulation ratio for Cmax was calculated as Cmax, after third dose / Cmax, after first dose.</description>
          <population>PK analysis set included subjects who received active treatment (MSB0010841) without protocol deviations affecting PK, and who provide evaluable PK data. Here “Number of participants analyzed” signifies those subjects who were evaluable for this outcome measure.</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.56" spread="17.9"/>
                    <measurement group_id="O2" value="1.52" spread="23.5"/>
                    <measurement group_id="O3" value="1.56" spread="34.1"/>
                    <measurement group_id="O4" value="1.81" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Accumulation Ratio of AUC (Racc(AUC))</title>
        <description>Accumulation ratio for AUC, calculated as area under the serum concentration-time curve within one complete dosing interval at third dose divided by area under the serum concentration-time curve within one complete dosing interval at first dose.</description>
        <time_frame>0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-first dose (Day 1) and 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)</time_frame>
        <population>PK analysis set included subjects who received active treatment (MSB0010841) without protocol deviations affecting PK, and who provide evaluable PK data. Here “Number of participants analyzed” signifies those subjects who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>MSB0010841 30 mg</title>
            <description>MSB0010841(Anti- IL-17A/F Nanobody) was administered at a dose of 30 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>MSB0010841 60 mg</title>
            <description>MSB0010841 was administered at a dose of 60 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>MSB0010841 120 mg</title>
            <description>MSB0010841 was administered at a dose of 120 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O4">
            <title>MSB0010841 240 mg</title>
            <description>MSB0010841 was administered at a dose of 240 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Accumulation Ratio of AUC (Racc(AUC))</title>
          <description>Accumulation ratio for AUC, calculated as area under the serum concentration-time curve within one complete dosing interval at third dose divided by area under the serum concentration-time curve within one complete dosing interval at first dose.</description>
          <population>PK analysis set included subjects who received active treatment (MSB0010841) without protocol deviations affecting PK, and who provide evaluable PK data. Here “Number of participants analyzed” signifies those subjects who were evaluable for this outcome measure.</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.61" spread="15.9"/>
                    <measurement group_id="O2" value="1.50" spread="18.4"/>
                    <measurement group_id="O3" value="1.61" spread="27.4"/>
                    <measurement group_id="O4" value="1.83" spread="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Observed Concentration (Cmax) Post Second Dose of MSB0010841</title>
        <time_frame>0 hours (pre-dose), 24, 72, 96, 168, 336 hours post-second dose (Day 15)</time_frame>
        <population>PK analysis set included subjects who received active treatment (MSB0010841) without protocol deviations affecting PK, and who provide evaluable PK data. Here &quot;Number of subjects analyzed&quot; signifies those subjects who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>MSB0010841 30 mg</title>
            <description>MSB0010841(Anti- IL-17A/F Nanobody) was administered at a dose of 30 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>MSB0010841 60 mg</title>
            <description>MSB0010841 was administered at a dose of 60 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>MSB0010841 120 mg</title>
            <description>MSB0010841 was administered at a dose of 120 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O4">
            <title>MSB0010841 240 mg</title>
            <description>MSB0010841 was administered at a dose of 240 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Concentration (Cmax) Post Second Dose of MSB0010841</title>
          <population>PK analysis set included subjects who received active treatment (MSB0010841) without protocol deviations affecting PK, and who provide evaluable PK data. Here &quot;Number of subjects analyzed&quot; signifies those subjects who were evaluable for this outcome measure.</population>
          <units>mcg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.26" spread="32.7"/>
                    <measurement group_id="O2" value="9.06" spread="24.2"/>
                    <measurement group_id="O3" value="18.59" spread="23.1"/>
                    <measurement group_id="O4" value="30.98" spread="25.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Observed Serum Concentration Immediately Before Second Dose (Cpre) of MSB0010841</title>
        <description>The observed serum concentration immediately before second dose.</description>
        <time_frame>Pre-dose (0 hours) on Day 15</time_frame>
        <population>PK analysis set included subjects who received active treatment (MSB0010841) without protocol deviations affecting PK, and who provide evaluable PK data. Here “Number of participants analyzed” signifies those subjects who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>MSB0010841 30 mg</title>
            <description>MSB0010841(Anti- IL-17A/F Nanobody) was administered at a dose of 30 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>MSB0010841 60 mg</title>
            <description>MSB0010841 was administered at a dose of 60 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>MSB0010841 120 mg</title>
            <description>MSB0010841 was administered at a dose of 120 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O4">
            <title>MSB0010841 240 mg</title>
            <description>MSB0010841 was administered at a dose of 240 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Observed Serum Concentration Immediately Before Second Dose (Cpre) of MSB0010841</title>
          <description>The observed serum concentration immediately before second dose.</description>
          <population>PK analysis set included subjects who received active treatment (MSB0010841) without protocol deviations affecting PK, and who provide evaluable PK data. Here “Number of participants analyzed” signifies those subjects who were evaluable for this outcome measure.</population>
          <units>mcg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.65" spread="30.2"/>
                    <measurement group_id="O2" value="3.74" spread="37.9"/>
                    <measurement group_id="O3" value="6.34" spread="38.3"/>
                    <measurement group_id="O4" value="11.44" spread="18.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With 50% or 75% Improvement From Baseline in Psoriasis Area and Severity Index (PASI) Score</title>
        <description>PASI: a physician assessed index that measured psoriasis severity and evaluated erythema, infiltration, and desquamation (scaling) on different body areas including the head, upper extremities, the trunk, and lower extremities. T Erythema, infiltration, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) was multiplied by the degree of involvement for each anatomic region and then multiplied by a constant. These values for each anatomic region are summed to yield the PASI score. PASI score ranged from 0 to 72, with higher scores reflecting greater disease severity. PASI 50% or 75% was defined as the percentage of participants who achieved &gt;=50 or 75% improvement in PASI score from Baseline.</description>
        <time_frame>Baseline up to Day 85</time_frame>
        <population>Safety analysis set included all 41 subjects who received at least 1 dose of IMP (MSB0010841 or placebo).</population>
        <group_list>
          <group group_id="O1">
            <title>MSB0010841 30 mg</title>
            <description>MSB0010841 (Anti- IL-17A/F Nanobody) was administered at a dose of 30 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>MSB0010841 60 mg</title>
            <description>MSB0010841 was administered at a dose of 60 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>MSB0010841 120 mg</title>
            <description>MSB0010841 was administered at a dose of 120 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O4">
            <title>MSB0010841 240 mg</title>
            <description>MSB0010841 was administered at a dose of 240 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo matched to MSB0010841 was administered as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With 50% or 75% Improvement From Baseline in Psoriasis Area and Severity Index (PASI) Score</title>
          <description>PASI: a physician assessed index that measured psoriasis severity and evaluated erythema, infiltration, and desquamation (scaling) on different body areas including the head, upper extremities, the trunk, and lower extremities. T Erythema, infiltration, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) was multiplied by the degree of involvement for each anatomic region and then multiplied by a constant. These values for each anatomic region are summed to yield the PASI score. PASI score ranged from 0 to 72, with higher scores reflecting greater disease severity. PASI 50% or 75% was defined as the percentage of participants who achieved &gt;=50 or 75% improvement in PASI score from Baseline.</description>
          <population>Safety analysis set included all 41 subjects who received at least 1 dose of IMP (MSB0010841 or placebo).</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PASI-50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="100"/>
                    <measurement group_id="O4" value="100"/>
                    <measurement group_id="O5" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PASI-75</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="100"/>
                    <measurement group_id="O4" value="100"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Day 43</title>
        <description>PASI: a physician assessed index that measured psoriasis severity and evaluated erythema, infiltration, and desquamation (scaling) on different body areas including the head, upper extremities, the trunk, and lower extremities. T Erythema, infiltration, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) was multiplied by the degree of involvement for each anatomic region and then multiplied by a constant. These values for each anatomic region are summed to yield the PASI score. PASI score ranged from 0 to 72, with higher scores reflecting greater disease severity. PASI 50% or 75% was defined as the percentage of subjects who achieved &gt;=50 or 75% improvement in PASI score from Baseline.</description>
        <time_frame>Baseline, Day 43</time_frame>
        <population>Safety analysis set included all 41 subjects who received at least one dose of IMP (MSB0010841 or placebo).</population>
        <group_list>
          <group group_id="O1">
            <title>MSB0010841 30 mg</title>
            <description>MSB0010841 (Anti- IL-17A/F Nanobody) was administered at a dose of 30 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>MSB0010841 60 mg</title>
            <description>MSB0010841 was administered at a dose of 60 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>MSB0010841 120 mg</title>
            <description>MSB0010841 was administered at a dose of 120 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O4">
            <title>MSB0010841 240 mg</title>
            <description>MSB0010841 was administered at a dose of 240 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo matched to MSB0010841 was administered as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Day 43</title>
          <description>PASI: a physician assessed index that measured psoriasis severity and evaluated erythema, infiltration, and desquamation (scaling) on different body areas including the head, upper extremities, the trunk, and lower extremities. T Erythema, infiltration, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) was multiplied by the degree of involvement for each anatomic region and then multiplied by a constant. These values for each anatomic region are summed to yield the PASI score. PASI score ranged from 0 to 72, with higher scores reflecting greater disease severity. PASI 50% or 75% was defined as the percentage of subjects who achieved &gt;=50 or 75% improvement in PASI score from Baseline.</description>
          <population>Safety analysis set included all 41 subjects who received at least one dose of IMP (MSB0010841 or placebo).</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.91" spread="5.75"/>
                    <measurement group_id="O2" value="19.76" spread="4.79"/>
                    <measurement group_id="O3" value="23.35" spread="6.60"/>
                    <measurement group_id="O4" value="18.38" spread="6.07"/>
                    <measurement group_id="O5" value="25.49" spread="5.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 43</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.93" spread="4.76"/>
                    <measurement group_id="O2" value="-17.99" spread="5.52"/>
                    <measurement group_id="O3" value="-21.70" spread="8.52"/>
                    <measurement group_id="O4" value="-16.68" spread="8.38"/>
                    <measurement group_id="O5" value="-5.43" spread="7.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Static Physician’s Global Assessment (sPGA) Score of Minimal or Clear and With at Least 2 Level Reduction From Baseline</title>
        <description>The static Physician’s Global Assessment (sPGA) scale rated the investigator’s overall clinical assessment of a subjects plaque thickness, erythema, and scaling on a 6-point scale ranging from 0 (clear, except for residual discoloration) to 5 (majority of plaques have severe thickness, erythema, and scale). To assign a sPGA score, the investigator examined all psoriatic lesions and assigned a severity score ranging from 0 to 5 for thickness, erythema, and scaling. Scores for thickness, erythema, and scaling are summed and the mean of these 3 scores equals the overall sPGA score. Overall sPGA score ranged from 0 to 5, where lower scores indicate clinical improvement. Percentage of subjects who achieved a sPGA rating of 0 (clear) or 1 (minimal) and had at Least 2 level reduction from Baseline score were reported.</description>
        <time_frame>Day 8, 15, 22, 29, 36, 43, 50, 85</time_frame>
        <population>Safety analysis set included all 41 subjects who received at least one dose of IMP (MSB0010841 or placebo).</population>
        <group_list>
          <group group_id="O1">
            <title>MSB0010841 30 mg</title>
            <description>MSB0010841 was administered at a dose of 30 mg as SC injection every other week for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>MSB0010841 60 mg</title>
            <description>MSB0010841 was administered at a dose of 60 mg as SC injection every other week for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>MSB0010841 120 mg</title>
            <description>MSB0010841 was administered at a dose of 120 mg as SC injection every other week for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O4">
            <title>MSB0010841 240 mg</title>
            <description>MSB0010841 was administered at a dose of 240 mg as SC injection every other week for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo matched to MSB0010841 was administered as SC injection every other week for a total duration of 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Static Physician’s Global Assessment (sPGA) Score of Minimal or Clear and With at Least 2 Level Reduction From Baseline</title>
          <description>The static Physician’s Global Assessment (sPGA) scale rated the investigator’s overall clinical assessment of a subjects plaque thickness, erythema, and scaling on a 6-point scale ranging from 0 (clear, except for residual discoloration) to 5 (majority of plaques have severe thickness, erythema, and scale). To assign a sPGA score, the investigator examined all psoriatic lesions and assigned a severity score ranging from 0 to 5 for thickness, erythema, and scaling. Scores for thickness, erythema, and scaling are summed and the mean of these 3 scores equals the overall sPGA score. Overall sPGA score ranged from 0 to 5, where lower scores indicate clinical improvement. Percentage of subjects who achieved a sPGA rating of 0 (clear) or 1 (minimal) and had at Least 2 level reduction from Baseline score were reported.</description>
          <population>Safety analysis set included all 41 subjects who received at least one dose of IMP (MSB0010841 or placebo).</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="38"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="56"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="50"/>
                    <measurement group_id="O3" value="50"/>
                    <measurement group_id="O4" value="67"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="63"/>
                    <measurement group_id="O3" value="88"/>
                    <measurement group_id="O4" value="78"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="88"/>
                    <measurement group_id="O3" value="75"/>
                    <measurement group_id="O4" value="67"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="88"/>
                    <measurement group_id="O3" value="75"/>
                    <measurement group_id="O4" value="67"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="88"/>
                    <measurement group_id="O3" value="100"/>
                    <measurement group_id="O4" value="89"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                    <measurement group_id="O2" value="88"/>
                    <measurement group_id="O3" value="88"/>
                    <measurement group_id="O4" value="100"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Percent Change From Baseline in the Body Surface Area (BSA) Affected by Psoriasis at Day 8, 15, 22, 29, 36, 43, 50 and 85</title>
        <description>The BSA is the physician’s evaluation for the extent of disease. The entire body area is divided into 4 districts: head, upper limbs, trunk and lower limbs to which corresponds the 10%, 20%, 30% and 40% of the entire body surface respectively. The investigator assesses the percentage of the subjects' body surface area affected by psoriasis in each district. The final affected BSA value is the sum of the percentage of each district.</description>
        <time_frame>Baseline, Day 8, 15, 22, 29, 36, 43, 50 and 85</time_frame>
        <population>Safety analysis set included all 41 subjects who received at least 1 dose of IMP (MSB0010841 or placebo). Here &quot;n&quot; signifies those subjects who were evaluable for this outcome measure at the specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>MSB0010841 30 mg</title>
            <description>MSB0010841 (Anti- IL-17A/F Nanobody) was administered at a dose of 30 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>MSB0010841 60 mg</title>
            <description>MSB0010841 was administered at a dose of 60 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>MSB0010841 120 mg</title>
            <description>MSB0010841 was administered at a dose of 120 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O4">
            <title>MSB0010841 240 mg</title>
            <description>MSB0010841 was administered at a dose of 240 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo matched to MSB0010841 was administered as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Change From Baseline in the Body Surface Area (BSA) Affected by Psoriasis at Day 8, 15, 22, 29, 36, 43, 50 and 85</title>
          <description>The BSA is the physician’s evaluation for the extent of disease. The entire body area is divided into 4 districts: head, upper limbs, trunk and lower limbs to which corresponds the 10%, 20%, 30% and 40% of the entire body surface respectively. The investigator assesses the percentage of the subjects' body surface area affected by psoriasis in each district. The final affected BSA value is the sum of the percentage of each district.</description>
          <population>Safety analysis set included all 41 subjects who received at least 1 dose of IMP (MSB0010841 or placebo). Here &quot;n&quot; signifies those subjects who were evaluable for this outcome measure at the specified time points.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Day 8 (n=8,8,8,8,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="1.14"/>
                    <measurement group_id="O2" value="-30.0" spread="31.23"/>
                    <measurement group_id="O3" value="-13.7" spread="15.13"/>
                    <measurement group_id="O4" value="-12.5" spread="23.81"/>
                    <measurement group_id="O5" value="2.9" spread="23.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 15 (n=8,8,8,8,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="1.14"/>
                    <measurement group_id="O2" value="-33.1" spread="35.97"/>
                    <measurement group_id="O3" value="-20.5" spread="10.98"/>
                    <measurement group_id="O4" value="-51.1" spread="43.17"/>
                    <measurement group_id="O5" value="-4.2" spread="12.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 22 (n=8,8,8,8,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.6" spread="24.90"/>
                    <measurement group_id="O2" value="-40.2" spread="40.68"/>
                    <measurement group_id="O3" value="-42.6" spread="27.15"/>
                    <measurement group_id="O4" value="-68.5" spread="38.71"/>
                    <measurement group_id="O5" value="-5.1" spread="12.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 29 (n=8,8,8,8,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.6" spread="26.35"/>
                    <measurement group_id="O2" value="-44.1" spread="42.53"/>
                    <measurement group_id="O3" value="-55.9" spread="36.56"/>
                    <measurement group_id="O4" value="-82.9" spread="34.46"/>
                    <measurement group_id="O5" value="-0.1" spread="26.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 36 (8,8,7,7,7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.4" spread="22.96"/>
                    <measurement group_id="O2" value="-52.7" spread="37.57"/>
                    <measurement group_id="O3" value="-64.6" spread="37.65"/>
                    <measurement group_id="O4" value="-83.5" spread="31.60"/>
                    <measurement group_id="O5" value="-0.5" spread="27.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 43 (8,8,8,9,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-52.6" spread="32.91"/>
                    <measurement group_id="O2" value="-65.2" spread="28.61"/>
                    <measurement group_id="O3" value="-75.4" spread="37.35"/>
                    <measurement group_id="O4" value="-82.2" spread="36.64"/>
                    <measurement group_id="O5" value="-1.5" spread="27.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 50 (n=8,8,8,9,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-56.2" spread="34.71"/>
                    <measurement group_id="O2" value="-69.4" spread="25.85"/>
                    <measurement group_id="O3" value="-79.1" spread="32.30"/>
                    <measurement group_id="O4" value="-82.2" spread="36.64"/>
                    <measurement group_id="O5" value="-10.0" spread="17.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 85 (8,8,8,9,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-60.4" spread="33.51"/>
                    <measurement group_id="O2" value="-61.3" spread="33.89"/>
                    <measurement group_id="O3" value="-82.1" spread="31.05"/>
                    <measurement group_id="O4" value="-95.5" spread="11.02"/>
                    <measurement group_id="O5" value="-13.0" spread="20.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Exacerbation of Psoriasis</title>
        <description>Psoriasis exacerbation was defined as either a worsening of 25% over the baseline value of the PASI score (PASI score at any visit &gt;=125% of baseline PASI).</description>
        <time_frame>Baseline up to Day 85</time_frame>
        <population>Safety analysis set included all 41 subjects who received at least 1 dose of IMP (MSB0010841 or placebo).</population>
        <group_list>
          <group group_id="O1">
            <title>MSB0010841 30 mg</title>
            <description>MSB0010841 (Anti- IL-17A/F Nanobody) was administered at a dose of 30 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>MSB0010841 60 mg</title>
            <description>MSB0010841 was administered at a dose of 60 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>MSB0010841 120 mg</title>
            <description>MSB0010841 was administered at a dose of 120 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O4">
            <title>MSB0010841 240 mg</title>
            <description>MSB0010841 was administered at a dose of 240 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo matched to MSB0010841 was administered as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Exacerbation of Psoriasis</title>
          <description>Psoriasis exacerbation was defined as either a worsening of 25% over the baseline value of the PASI score (PASI score at any visit &gt;=125% of baseline PASI).</description>
          <population>Safety analysis set included all 41 subjects who received at least 1 dose of IMP (MSB0010841 or placebo).</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline up to Day 85</time_frame>
      <group_list>
        <group group_id="E1">
          <title>MSB0010841 30 mg</title>
          <description>MSB0010841(Anti- IL-17A/F Nanobody) was administered at a dose of 30 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
        </group>
        <group group_id="E2">
          <title>MSB0010841 60 mg</title>
          <description>MSB0010841 was administered at a dose of 60 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
        </group>
        <group group_id="E3">
          <title>MSB0010841 120 mg</title>
          <description>MSB0010841 was administered at a dose of 120 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
        </group>
        <group group_id="E4">
          <title>MSB0010841 240 mg</title>
          <description>MSB0010841 was administered at a dose of 240 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
        </group>
        <group group_id="E5">
          <title>Placebo</title>
          <description>Placebo matched to MSB0010841 was administered as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Acute vestibular syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoaesthesia oral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Injection site urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Bacterial vaginosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Sunburn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Fibrin D dimer increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Blood cholesterol increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Glucose urine present</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase MB increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Blood iron decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Protein urine present</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Urine ketone body present</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Leukocyturia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Catarrh</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>As AUCextra was more than 20% of AUC0-inf after first dose, AUCextra and all values derived from λz were regarded as implausible and &quot;AUC0-inf&quot;, &quot;MRT0-inf&quot;, &quot;t1/2&quot;, &quot;λz&quot;, &quot;CL/f&quot;, and &quot;Vz/f&quot; were not calculated after first dose.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Merck KGaA Communication Center</name_or_title>
      <organization>Merck Healthcare, a business of Merck KGaA, Darmstadt, Germany</organization>
      <phone>+49-6151-72-5200</phone>
      <email>service@merckgroup.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

